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Familial dilated cardiomyopathy (DCM) is mostly caused by mutations in genes
encoding cytoskeletal and sarcomeric proteins. In the pediatric population, DCM is the
predominant type of primitive myocardial disease. A severe form of DCM is associated
with mutations in the DMD gene encoding dystrophin, which are the cause of Duchenne
Muscular Dystrophy (DMD). DMD-associated cardiomyopathy is still poorly understood
and orphan of a specific therapy. In the last 5 years, a rise of interest in disease models
using human induced pluripotent stem cells (hiPSCs) has led to more than 50 original
studies on DCM models. In this review paper, we provide a comprehensive overview
on the advances in DMD cardiomyopathy disease modeling and highlight the most
remarkable findings obtained from cardiomyocytes differentiated from hiPSCs of DMD
patients. We will also describe how hiPSCs based studies have contributed to the
identification of specific myocardial disease mechanisms that may be relevant in the
pathogenesis of DCM, representing novel potential therapeutic targets.
Keywords: dilated cardiomyopathy (DCM), duchenne muscular dystrophy (DMD), dystrophin (DMD), hiPSC-
cardiomyocyte, stem cell models
Abbreviations: AAV, Adeno-associated virus; ABCC9, Sulfonylurea receptor 2A, component of ATP-sensitive potassium
channel; ABD1, actin-binding domain; ACTC1, α-cardiac actin; ACTN2, α-actinin 2; AF, atrial fibrillation; ANKRD1, Cardiac
ankyrin repeat protein; ARVC, arrhythmogenic right ventricular cardiomyopathy; BAG3, BCL2-associated athanogene 3;
BMD, Becker Muscular Dystrophy; CM, Cardiomyocytes; CMR, cardiac magnetic resonance; CRISPR-Cas9, Clustered
Regularly Interspaced Short Palindromic Repeats; CRYAB, α-B-crystallin; CSRP3, Muscle LIM protein; DCM, Dilated
cardiomyopathy; DES, Desmin; DGC, dystrophin glycoproteic complex; DMD, Duchenne Muscular Dystrophy; DMD,
dystrophin gene; DNAJC19, HSP40 homolog, C19; Dp427, Full-length dystrophin isoform (427 kDa); Dp71, Dystrophin
isoform (71 kDa); DSP, Desmoplakin; ECG, electrocardiogram; EHT, engineered heart tissue; EMD, Emerin; fast kREL, fast
phase of myofibril relaxation; FLNC, Filamin C; HCM, hypertrophic cardiomyopathy; HF, Heart failure; hiPSC, Human
induced pluripotent stem cell; HT, heart transplantation; ICD, implantable cardioverter defibrillators; kACT , myofibril kinetic
of force development; KCNQ1, Potassium channel; LDB3, Cipher/ZASP; LMNA, Lamin A/C; LQT, long QT syndrome; LV,
left ventricle; LVEF, left ventricular ejection fraction; LVNC, left ventricular non-compaction; MF, myocardial fibrosis; MYH7,
β-Myosin heavy chain; NEBL, Nebulette; nNOS, nitric oxide synthase; OMT, optimal medical therapy; PAM, protospacer
adjacent motif; PLN, Phospholamban; PMO, phosphorodiamidate morpholino oligomer; RBM20, RNA-binding protein 20;
RCM, restrictive cardiomyopathy; RCT, randomized control trial; SCD, sudden cardiac death; SCN5A, Type V voltage-
gatedcardiac Na channel; SGCA, SGCB, SGCD, α-/β-/δ-Sarcoglycan; slow kREL, slow linear phase of myofibril relaxation;
TALEN, transcription activator-like effector nucleases; TAZ/G4.5, Tafazzin; TCAP, Titin-cap/telethonin; TNNC1, Cardiac
troponin C; TNNI3, Cardiac troponin I; TNNI3K, Troponin I–interactingkinase; TNNT2, Cardiac troponin T; TPM1,
α-Tropomyosin; TTN, Titin; VCL, Metavinculin; VF, ventricular fibrillation; VT, ventricular tachycardia.
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HIGHLIGHTS
• Mutations in the DMD gene (encoding dystrophin) account
for 2% of inherited dilated cardiomyopathy (DCM). Advances
in in vitro disease modeling using induced pluripotent
stem cell-derived cardiomyocytes (hiPSC-CMs) may help
develop specific therapies aimed at restoring or blunting
myocardial damage and dysfunction in Duchenne and Becker
Muscular Dystrophy.
• This review focuses on the physiological role of dystrophin
in cardiomyocyte function during cardiac development and
disease progression. The pathological mechanisms caused
by the absence of dystrophin or the presence of truncated
dystrophin isoforms are discussed. We provide an overview
of the most recent and remarkable results obtained using
hiPSC-CM lines with DMD mutations.
• Many studies employed hiPSC-CMs for pilot tests of gene
therapy strategies. In vitro models such as DMD patient-
cardiomyocytes offers a limitless source of human tissue to
explore novel disease mechanisms that may represent targets
for pharmacological intervention, tested and validated using
novel high-throughput cell-screening techniques. Dystrophin-
associated cardiomyopathy is an example of a rare cardiac
disease where stem cell-based disease-modeling may help
developing truly “patient-specific” therapeutic strategies.
Mutations in the dystrophin gene at the Xp21.1 locus are
associated with devastating X-linked skeletal muscle disorders,
such as Duchenne or Becker muscular dystrophies (DMD/BMD),
and account for <2% of dilated cardiomyopathy (DCM) cases.
The incidence of DMD is 1/5,000 male births (Mendell et al.,
2012). Despite its low prevalence (<3/10,000), dystrophin-
associated cardiomyopathy is the form of DCM that has been
modeled in vitro more extensively using induced pluripotent
stem cell-derived cardiomyocytes (iPSC-CMs) from patients.
As a case in point, twenty original studies based on the
use of DMD/BMD iPS-derived cell lines are present in the
recent literature (2015–2019), as opposed to only few isolated
examples for other genetically determined DCMs (Table 1). Why
is dystrophin-associated cardiomyopathy more widely studied
in vitro compared to other forms of DCM? And are DMD/BMD
in vitro models specific in recapitulating dystrophin-related
pathophysiology, or can lessons be learned regarding the wider
spectrum of DCM?
The first answer is simple: an intense and growing interest
in DMD/BMD models derives from its potential for gene
therapy. Given the severity of skeletal muscle damage associated
with dystrophin depletion, a number of gene-targeted therapies
aimed at inducing dystrophin expression have been developed.
These promising gene-editing approaches have been developed
for DMD to a level far beyond what has been achieved for
any other cardiac or skeletal muscle diseases. Gene-editing
strategies are being thoroughly evaluated in vitro in hopes of
improving/delaying cardiac as well as muscular involvement
in DMD patients.
The second issue is far more challenging and largely
unresolved. Lack of dystrophin and of its stabilizing effects on
the cytoskeleton causes a variety of downstream pathogenic
mechanisms, ultimately leading to calcium dysregulation and
sarcomere dysfunction. Whether and how all or part of
these pathways are relevant to other forms of genetically-
driven or acquired DCM, remains to be studied. In light of
the advancements introduced by iPSC-derived cardiomyocyte
modeling, the present review aims to describe the principal
pathophysiological mechanisms associated with DMD, with the
purpose of defining to what extent these mechanisms are specific
to dystrophin depletion or rather, they are part of the wider
spectrum of DCM-related cardiac abnormalities. Finally, we will




DCM is a disease of the myocardium characterized by left
ventricular (LV) dilatation and dysfunction with an estimated
prevalence of 1:2,500, an incidence of 7:100,000 and a male to
female ratio of 3:1, in adults (Rakar et al., 1997). Recent estimates
suggest a considerably higher prevalence of≥1 in 250 individuals
(Hershberger et al., 2013). In the pediatric population, DCM is
the predominant type of cardiomyopathy and its incidence is
higher in the first year of life (Lipshultz et al., 2003). DCM is one
of the leading causes of heart failure (HF) and the most frequent
indication for heart transplantation (Japp et al., 2016).
In almost 40% of cases, DCM is genetically determined
and associated with mutations in genes coding for titin (19–
25%), lamin (5–6%), and sarcomeric thin (1–3%) or thick
(3–4%) filament proteins. A variety of pathways and cellular
structures are affected by these mutations with negative effects on
mechanisms like calcium homeostasis, generation–transmission
of mechanic force in the myocardium, muscle contraction and
ion channel function. The prevailing pattern of inheritance
is autosomal dominant, with incomplete, penetrance, and
variable age-related expression. The complex interaction between
common and rare variants, the presence of additional modifier
gene mutations or polymorphisms, as well as a number of
environmental factors, may be responsible for the clinical
heterogeneity of DCM even in families carrying the same
pathogenic gene variant (Bondue et al., 2018). While the etiology
of a wide proportion of cases remains unknown after genetic
testing (the so-called “idiopathic” DCM), these apparently “non-
genetic” forms, even when clearly acquired (e.g., alcohol- or
chemotherapy-related or post-partum cardiomyopathies), are
often influenced by the individual genetic profile (McNally and
Mestroni, 2017). On the other hand, the pathogenicity of a
gene mutation is modulated by interfering factors like age, the
hormonal milieu, the status if the innate immune system, the
presence of comorbidities such as chronic inflammatory diseases
or hypertension, inherited mitochondrial alterations or the
exposure to specific environmental triggers (such as cardio-toxic
substances or drugs); all these can profoundly alter the clinical
phenotype as well as the outcome. In this complex scenario,
understanding genotype–phenotype correlations represents the
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TABLE 1 | Principal pathogenic gene mutations described in genetic DCM along with their clinical and cellular phenotype.
Gene Prevalence Clinical phenotype #hiPSC studies (References) Functional output
Titin (TTN) 19–25% of familial
forms 11–18% of
sporadic forms
Usually milder forms of DCM, with LV reverse
remodeling described after OMT. Can be
associated with tibial muscle dystrophy and
HCM (McNally and Mestroni, 2017). Truncating
variants are related to alterations in
mitochondrial function, increased interstitial
fibrosis and reduced hypertrophy, along with
increased ventricular arrhythmias at long-term
follow-up, with a similar survival and overall
cardiac function with respect to idiopathic DCM
(Verdonschot et al., 2018).
5 (Hinson et al., 2015;
Streckfuss-Bomeke et al., 2017;
Chopra et al., 2018; Schick et al.,
2018; Zaunbrecher et al., 2019)
Contractile deficit
Lamin A/C (LMNA) 5–6% of genetic
DCM
Malignant DCM characterized by young onset,
high penetrance, dysrhythmias (sinus node
dysfunction, AF, atrioventricular node
dysfunction, VT, VF, SCD), LV dysfunction and
HF with reduced survival and frequent need for
HT. Cardiac conduction system disease usually
precedes the development of LV dilation and
dysfunction (Hasselberg et al., 2018).
6 (Siu et al., 2012; Wyles et al.,
2016a; Lee et al., 2017; Bertero
et al., 2019; Salvarani et al., 2019;







3–4% of DCM Sarcomeric rare variant carriers show a more
rapid progression toward death or HT
compared to non-carriers, particularly after




3% of DCM Clinical and prognostic profiles depend on type
of mutation: carriers of Arg92Gln mutation have
a worse prognosis than those with other
mutations in TNNT2 or other sarcomeric genes
(Ripoll-Vera et al., 2016).
6 (Sun et al., 2012; Wu et al., 2015;
Broughton et al., 2016; Burridge
et al., 2016; Wang L. et al., 2018;








2–3% of DCM Arrhythmias (commonly AF) and myocyte
dysfunction leading to progressive deterioration
of LV systolic function (Bondue et al., 2018).
Overlapping phenotypes: LQT, Brugada.





1–5% of DCM Malignant arrhythmic phenotype with high
frequency of AF and progressive HF (Ripoll-Vera
et al., 2016).
3 (Wyles et al., 2016a,b;




Desmoplakin (DSP) 2% of DCM Associated with Carvajal syndrome (autosomal
recessive genetic disorder characterized by
woolly hair, striate palmoplantar keratoderma
and DCM). Additional phenotypic signs: dental
abnormalities and leukonychia. LV dilatation
usually asymptomatic at an early age. DCM
progresses rapidly, leading to HF or SCD in
adolescence (Yermakovich et al., 2018).





Associated with Duchenne and Becker
muscular dystrophy. Severe cardiac
involvement in Duchenne (milder and later
onset in Becker muscular dystrophy) with
supraventricular arrhythmias, atrio-ventricular
blocks and right bundle branch block,
progressive LV dysfunction and HF (Mestroni
et al., 2014).
20 (Dick et al., 2013; Guan et al.,
2014; Zatti et al., 2014; Lin et al.,
2015; Macadangdang et al., 2015;
Japp et al., 2016; Nanni et al.,
2016; Young et al., 2016;
Kyrychenko et al., 2017; Zhang
et al., 2017; Long et al., 2018;
Caluori et al., 2019; Eisen et al.,
2019; Farini et al., 2019; Jelinkova
et al., 2019; Min et al., 2019; Pioner
et al., 2019a; Sato et al., 2019;







1–2% of DCM Overlapping phenotypes: LVNC, HCM (McNally
and Mestroni, 2017)
1 (Takasaki et al., 2018) Sarcomere defects
(Continued)
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TABLE 1 | Continued
Gene Prevalence Clinical phenotype #hiPSC studies (References) Functional output
Desmin (DES) 1–2% of DCM
(Taylor et al., 2007)
Malignant phenotype associated with
desminopathies and myofibrillar myopathy. Can
cause a spectrum of phenotypes from skeletal
myopathy, mixed skeletal–cardiac disease
(“desmin-related myopathy”), and
cardiomyopathy (DCM as well as HCM or
RCM). DCM is typically preceded by skeletal
myopathy and can be associated with
conduction defects (Mestroni et al., 2014).
1 (Tse et al., 2013) DES protein
aggregates
Filamin C (FLNC) 1% of DCM Cardiomyopathy associated with myofibrillar
myopathy and LVNC; high rate of ventricular
arrhythmias and SCD (particularly in truncating
variants) (Ader et al., 2019).
?
Metavinculin (VCL) 1% of DCM Can cause either DCM or HCM phenotype












Early onset DCM with lethal ventricular
arrhythmias. Low QRS complex potentials and
decreased R wave amplitude, negative T waves
in left precordial leads (Hof et al., 2019). PLN
R14del mutation associated with high risk for
malignant arrhythmias and end-stage HF from
late adolescence, can cause either a DCM
phenotype or ARVC (Mestroni et al., 2014).
A milder phenotype is also reported (DeWitt
et al., 2006).
4 (Karakikes et al., 2015; Stillitano
et al., 2016; Ceholski et al., 2018;







Rare Recessive mutations in δ-sarcoglycan linked to
limb girdle muscular dystrophy 2F, dominant
mutations in δ-sarcoglycan linked to DCM






Rare Familial atrial septal defect combined with a
late-onset DCM (Frank et al., 2019). Can be




Rare Overlapping phenotype: HCM (McNally and
Mestroni, 2017).










Rare Conduction defect, AF (McNally and Mestroni,
2017).
?






Rare Associated with myofibrillar myopathy (McNally
and Mestroni, 2017).




Rare Associated with protein aggregation myopathy
(McNally and Mestroni, 2017).




Rare Associated with limb-girdle muscular dystrophy




Rare Overlapping phenotype: HCM (McNally and
Mestroni, 2017).





Rare Associated with congenital heart disease




Rare Overlapping phenotype: LVNC (McNally and
Mestroni, 2017).
?
Nebulette (NEBL) Rare Overlapping phenotypes: LVNC, HCM (McNally
and Mestroni, 2017).
?
Emerin (EMD) Rare Associated with Emery–Dreifuss muscular
dystrophy (McNally and Mestroni, 2017).
1 (Shimojima et al., 2017) Calcium handling
abnormalities
(Continued)
Frontiers in Physiology | www.frontiersin.org 4 May 2020 | Volume 11 | Article 368
fphys-11-00368 May 10, 2020 Time: 19:26 # 5
Pioner et al. Impact of DMD-Stem Cell Modeling on DCM
TABLE 1 | Continued







Rare Associated with AF, Osteochondrodysplasia




Rare Associated with AF, LQT1, short QT1, Jervell





Rare Associated with 3-methylglutaconic aciduria,
type V (McNally and Mestroni, 2017).
1 (Rohani et al., 2020) Mitochondrial
abnormalities
Tafazzin (TAZ/G4.5) Rare Associated with LVNC, Barth syndrome,
endocardial fibroelastosis 2 (McNally and
Mestroni, 2017).
1 (Wang et al., 2014) Mitochondrial
defects; contractile
defects
ultimate challenge for translational research in the field
of cardiomyopathies.
Mutations in the TTN gene coding for titin, a giant
protein that works as a nano-spring, account for most known
genetic forms of DCM (19–25% of familial forms and 11–
18% of sporadic forms), with incomplete penetrance and
variable expression, frequently (but not always) presenting with
relatively mild phenotypes and slow progression (Bondue et al.,
2018). Conversely, mutations in the LMNA gene (lamin A/C,
representing 5–6% of genetic DCM) (Hasselberg et al., 2018),
FLNC (filamin C) (Ortiz-Genga et al., 2016), DES (desmin)
(Capetanaki et al., 2015), PLN (phospholamban) (Schmitt et al.,
2003), SCN5A (McNair et al., 2011), and mutations of RBM20,
the regulator of TTN splicing (Refaat et al., 2012), have been
identified as malignant causes of DCM, featuring a marked
arrhythmic propensity in patients. The electrical instability
characterizing these forms gives rise to a clinical overlap between
DCM, arrhythmogenic cardiomyopathy and channelopathies
(Table 1), as these different disease may share a similar cellular
and molecular basis of arrhythmogenesis, ultimately leading to
an increased risk of sudden cardiac death (Gigli et al., 2019).
Currently, lamin A/C gene mutations represent the only instance
where the presence of a specific genetic background per se
modifies clinical management, warranting consideration for the
implantation of cardioverter defibrillators (ICDs), regardless of
the severity of LV dysfunction (Priori et al., 2015).
CLINICAL PROFILE OF
DYSTROPHIN-ASSOCIATED DCM
DMD is a severe disorder diagnosed in childhood: without
supportive care, young men with DMD typically die in their
late teens or early 20 s. Historically, the most common cause
of death has been respiratory failure. However, with improved
respiratory support and the introduction of steroid therapy,
DMD cardiomyopathy is becoming an increasingly important
cause of morbidity and mortality, due to HF and ventricular
arrhythmias leading to sudden death (Eagle et al., 2002; McNally,
2007). From the clinical perspective, dystrophin-associated
cardiomyopathy is characterized by a consistently severe
phenotype (Table 1), and progresses relentlessly. Regional
progression of contractile impairment (from the inferolateral
wall to the rest of the LV) and diffuse/transmural replacement
fibrosis of the inferolateral LV wall are common features of
this form of DCM, relatively specific instrumental markers
that help distinguish DMD-cardiomyopathy from other forms
of DCM (Frankel and Rosser, 1976). LV dimensions and
myocardial stiffness increase progressively as the extension of
myocardial fibrosis (MF) increases (Figure 1). This, in turn,
leads to an increased cardiac workload and to the activation
of the renin angiotensin and the sympathetic nervous systems,
thus leading to worse cardiac function and more severe HF-
related symptoms and signs (Perloff, 1984). DMD patients
are usually extremely limited in their mobility since the first
decade, so that HF-related symptoms are often blunted by
the relative lack of physical activity: overt cardiac symptoms
have been reported in less than 30% of patients aged <18
(Nigro et al., 1990), underestimating the true extent and
prevalence of HF in DMD subjects. Patients may complain
about palpitations, dizziness or fainting, the latter commonly
associated with the presence of conduction abnormalities at
ECG (Fayssoil et al., 2017). Dyspnea is controlled by the
mechanical ventilation used for neuromuscular respiratory
failure: in this setting, peripheral edema and ascites are
common findings and are related to the ventilator-driven positive
intrathoracic pressures that reduce venous return (Nigro et al.,
1990). Pleural effusion is frequently seen in end-stage disease
(Fayssoil et al., 2014). Once HF appears the prognosis is
poor, despite the extensive use of the complete therapeutic
armamentarium including neuro-hormonal blockade. This is
in contrast with other genetic forms of DCM where therapy
can alter the progression of LV dysfunction and reverse
remodeling is common (Japp et al., 2016; Ader et al.,
2019). So far, no clear association between specific dystrophin
genotypes and the severity of the cardiac phenotype has
been established.
ECG abnormalities are often seen in DMD patients: the
most frequently reported changes are sinus tachycardia, short
PR intervals, deep and narrow “pseudo-necrosis” Q waves in
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FIGURE 1 | Cardiac magnetic resonance (CMR) cine imaging of a 24 years
old DMD patient. The collection of representative images from patients was
approved by the Ethical Committee of the Meyer Pediatric Hospital of Florence
in the context of a project funded by Telethon Italy (grant GGP16191).
Informed consent to patients was performed conform the declaration of
Helsinki. This data does not contribute to any novel finding. (A) Late
gadolinium-enhancement (B) left ventricular (LV) short-axis section images of a
patient with Duchenne muscular dystrophy (DMD). Yellow arrows indicate the
inferolateral subepicardial and midwall contiguous fibrosis; light blue arrows
indicate the anterior segment and the red arrows the posterolateral right
ventricle wall, both showing midwall fibrosis; CMR cine imaging (C) and late
gadolinium-enhancement (D) LV long-axis section images of the same patient
with DMD; yellow arrows indicate midwall fibrosis of the inferolateral segment.
inferolateral leads, tall R wave in the right precordial leads, right
bundle branch block and flat/inverted T waves (Manning and
Cropp, 1958; Takami et al., 2008). Arrhythmias such as atrial
flutter (Perloff, 1984), non-sustained or sustained ventricular
tachycardia (Corrado et al., 2002), complete atrioventricular
blocks and sick sinus syndrome (Fayssoil et al., 2008, 2010)
are seen mainly in patients with severe LV dysfunction (Gigli
et al., 2019). Doppler echocardiography typically shows early
LV dilatation and dysfunction, beginning in the pediatric
age range (McNally et al., 2015). Abnormal indices of
diastolic function have been proposed as early indicators
of myocardial abnormalities, preceding the development of
chamber enlargement and systolic dysfunction in the early stages
of DMD-related DCM (Markham et al., 2006). Likewise, regional
myocardial abnormalities have been reported in early stages,
affecting mainly the inferolateral region of the LV (Giatrakos
et al., 2006). Mitral functional regurgitation may also be present,
as a consequence of LV and mitral annulus dilation. In the recent
years, cardiac magnetic resonance (CMR) has been demonstrated
to be a valuable tool for detection of early cardiac involvement
and prediction of ventricular arrhythmias, cardiac remodeling
and long-term outcome (Mertens et al., 2008; McNally, 2017;
Silva et al., 2017).
Management of DMD cardiomyopathy is challenging, due
to the interplay of respiratory and cardiac manifestations,
poor response to standard treatment and severe systemic
manifestations of DMD. Moreover, large-scale randomized
clinical trials (RCTs) are rare in this field. Therefore, the
latest guidelines for the management of DMD cardiomyopathy
are mostly based on the consensus of experts from a wide
range of disciplines (Rakar et al., 1997; McNally et al., 2015).
Specifically, in the absence of dystrophin-specific targeted
cardiac therapies, the 2014 NHLBI working group recommended
the introduction of angiotensin-converting enzyme inhibitors
(ACEi) or angiotensin receptor blockers (ARBs) in boys
with DMD by 10 years of age, in addition to traditional
HF treatments (i.e., beta-blockers, mineralocorticoid receptor
antagonists, diuretics), as LV dysfunction progresses (Silva et al.,
2017). Steroid therapy primarily used to prolong ambulation,
also showed a cardioprotective effect in DMD patients (Markham
et al., 2008). Early initiation of noninvasive nocturnal ventilation
increases long-term survival (McNally and Mestroni, 2017). The
surveillance and management of arrhythmias in DMD patients
is currently based on general adult HF recommendations.
However, aggressive options such as an implantable cardioverter
defibrillator (ICD) or the use of cardiac resynchronization
therapy (CRT) is controversial in these patients, due to the limited
life expectancy and the increased procedural risk (Wang M. et al.,
2018). The same considerations apply to mechanical circulatory
support (Iodice et al., 2015) and left ventricular assist devices
(LVAD), rarely appropriate in this setting. Cardiac transplant is
generally contraindicated in DMD (Rakar et al., 1997).
DYSTROPHIN AND
DYSTROPHIN-GLYCOGEN COMPLEX
Dystrophin (DMD gene), the largest known gene in the human
genome (2.5 million base pairs) (Mandel, 1989), was also the first
found to be associated with DCM (Towbin et al., 1993). Ninety-
nine percent of the mRNA transcribed from DMD gene is made
by introns (non-coding sequences) and the coding sequence
accounts for 86 exons. The full-length mRNA (14,000 bp) has
a low tissue specificity and is detectable almost ubiquitously.
Conversely, protein expression is confined to striated muscle
and the neuropil (areas of the nervous system composed of
mostly unmyelinated axons, dendrites and glial cell processes
that forms a synaptically dense region containing a relatively
low number of cell bodies). The obvious discrepancy between
mRNA and protein distribution remains unresolved (Vogel and
Marcotte, 2012). High levels of full-length dystrophin protein
are present in both cardiac and skeletal myocytes, while the
protein has a lower expression in unmyelinated axons, dendrites
and glial cell processes forming synapsis-dense regions of the
brain (“neuropil”). Notably, the DMD gene produces many
protein isoforms for different tissue-specific functions (Muntoni
et al., 2003), owing to alternative splicing events. Splice variants
are formed by exon skipping, i.e., exclusion of exons from
primary transcripts, or by exon scrambling, i.e., subversion of the
reciprocal order of exons in the transcript (Muntoni, 2003).
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FIGURE 2 | Overview of full-length dystrophin in the context of other DCM-related proteins. The blow-up box, is a focus on full-length dystrophin structure and
interactions. Full-length dystrophin is a large rod-shaped protein with a molecular weight of 427 kDa composed by 4 structural domains. The amino (N)-terminal
domain has homology with α-actinin and binds, in particular, the F-actin; the central rod-domain contains 24–25 spectrin-like repeats the cysteine-rich domain
intereacting with syntrophin and sarcoglycans; the last carboxy (C)-terminal domain associates at the C-terminal with β-dystroglican and several other proteins to
form a major protein complex referred to as the dystrophin glycoproteic complex (DGC) (Hoffman et al., 1987; Ervasti and Campbell, 1993). The DGC consists of α-
and β-dystroglycan subunits, α-, β-, δ-, γ-, and ε-sarcoglycans, sarcospan, α- and β-syntrophins, α-dystrobrevin, and neuronal nitric oxide synthase (nNOS)
(Mosqueira et al., 2013). DGC related-pathways include Ca2+ homeostasis and E-C coupling, mitochondrial function, motor protein interaction (sarcomere/Z-band),
and gene expression. For instance, the acetylcholine receptor, the skeletal and cardiac isoforms of the voltage-gated sodium channels (Nav1.4 and Nav1.5,
respectively), the L-type Ca2+ channel, aquaporin, and stretch-activated channel or transient receptor potential (TRP) cation channels (Shirokova and Niggli, 2013)
are closely associated with the DGC via syntrophins. In the cardiac tissue, dystrophin is also associated to: Cavin-1 and Caveolin-3 (responsible for caveolae/T
tubule formation), Ahnak1 (modulates L-type Ca2+ channel), CryAB (involved in cytoprotection and antiapoptosis), and Cipher (plays a role in muscle contraction
maintaining the Z-line integrity and signaling). Dystrophin can be also target of phosphorylation by Calmodulin-dependent kinase II (CaMKII) that modulates the
affinity for F-actin and syntrophin (Madhavan and Jarrett, 1994). Other short isoforms of dystrophin come from spliced variants and are expressed in several other
tissues. In particular, the Dp71 is expressed in cardiac muscle and likely present in T-tubular membranes (Kaprielian and Severs, 2000; Kaprielian et al., 2000).
Full-length dystrophin (depicted in Figure 2, in the context
of other proteins associated with DCM) is a large rod-shaped
protein with a molecular weight of 427 kDa, composed by
4 structural domains. The amino (N)-terminal domain has
homology with α-actinin and binds, among other proteins,
F-actin. The central rod-domain contains 24–25 spectrin-like
repeats. The third one is a cysteine-rich domain. The last
carboxy (C)-terminal domain associates at the C-terminal with
several other proteins to form a major protein complex referred
to as the dystrophin-glycoproteic complex (DGC) (Hoffman
et al., 1987; Ervasti and Campbell, 1993). The DGC consists
of α- and β-dystroglycan subunits, α-, β-, δ-, γ -, and ε-
sarcoglycans, sarcospan, α- and β-syntrophins, α-dystrobrevin,
and neuronal nitric oxide synthase (nNOS) (Mosqueira et al.,
2013). A central role of dystrophin within this network is
evidenced by the collapse of the entire DGC in the absence of
dystrophin (Leyva-Leyva et al., 2018). Dystrophin is localized
at the cytoplasmic face of the muscle cell plasma membrane,
or sarcolemma, particularly within a cytoskeletal lattice termed
costameres. Through an extensive network of interacting proteins
(Ervasti, 2003) costameres physically couple the sarcolemma
with the Z disk of force-generating myofibrils (Rahimov
and Kunkel, 2013). In the striated muscle, the dystrophin
network covers almost the entire cytoplasmic surface of the
plasma membrane. It is strategically placed to serve in as a
shock absorber, promoting membrane stability and transduction
of mechanical force from the extracellular matrix during
muscle contraction/stretch. A single-molecule analysis by atomic
force microscopy revealed that dystrophin, by stretching with
stochastic unfolding and refolding of its central domain, is
able to keep elastic forces around 25 pN over a significant
length change up to ∼800 nm (90% of fully unfolded central
domain length), an extension range that is close to the
change of sarcomere length during myofilament contraction
in striated muscle (Le et al., 2018). In addition, the DGC
serves a variety of signaling pathways that regulate several
myocyte functions including Ca2+ homeostasis and excitation-
contraction coupling, mitochondrial function, motor protein
interaction, and gene expression. For instance, the acetylcholine
receptor, the skeletal and cardiac isoforms of the voltage-gated
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sodium channels (Nav1.4 and Nav1.5, respectively), the L-type
Ca2+ channel, aquaporin, stretch-activated channels and other
transient receptor potential (TRP) cation channels (Shirokova
and Niggli, 2013) are closely associated with the DGC via
syntrophins and are likely modulated by changes of dystrophin
conformation. Moreover, in the myocardium dystrophin appears
to serve as a signaling scaffold and membrane protein organizer,
targeted by numerous signaling molecules that participate in
a diverse set of pathways. For instance, it is also associated
with Cavin-1 and Caveolin-3 (responsible for caveolae/T tubule
formation), Ahnak1 (modulator of L-type Ca2+ channel),
CryAB (involved in cytoprotection and antiapoptosis), and
Cipher (involved in maintaining Z-line integrity and signaling).
Dystrophin can be a target of phosphorylation by Calmodulin-
dependent kinase II (CaMKII), modulating the affinity for
F-actin and syntrophin (Madhavan and Jarrett, 1994). Other
short isoforms of dystrophin originate from spliced variants
and are expressed elsewhere. Specifically, Dp71 is expressed in
cardiac muscle and is likely present in the T-tubular membrane
(Kaprielian and Severs, 2000; Kaprielian et al., 2000). Another
important protein is utrophin, a large (376 kDa) cytoskeletal
protein, autosomal paralog of dystrophin with similar binding
partners and structure that have been used to replace dystrophin
in striated muscle, as a therapeutic strategy for DMD (Blake et al.,
1996). Dystrophin and utrophin exhibit marked differences in
amino acid sequence, particularly within the large rod domain.
Thus, it is possible that proteins with unique specificity for
dystrophin or utrophin exist, though specific binding properties
remain to be identified.
Mutations in DMD that shift the reading frame generate a
truncated protein, which cannot anchor itself to the glycoprotein
complex. The protein is, therefore, unstable and present at
undetectable levels in muscle tissue. It is widely accepted that the
predominant functional consequence of the lack of dystrophin is
cellular vulnerability to mechanical stress associated with muscle
contraction. Membrane fragility and altered Ca2+ homeostasis
stem from the loss of dystrophin in both skeletal muscle
fibers and cardiomyocytes, as demonstrated by studies in DMD
animal models. These studies are consistent in showing that the
absence of dystrophin leads to altered myogenesis and myofiber
commitment in skeletal muscle, originally observed in X
Chromosome-Linked Muscular Dystrophy (mdx, genetic mouse
model of DMD that completely lacks full-length dystrophin)
mouse embryos (Merrick et al., 2009) and skeletal muscle biopsies
from human fetuses affected by DMD (Farini et al., 2016).
Myogenesis was severely disrupted in mdx embryos, which
displayed developmental delays including altered myotube size
and shape, lower number of myotubes, displacement defects
and aberrant Pax7-positive skeletal muscle stem cell behavior
(Merrick et al., 2009). Moreover, Dumont and collaborators
demonstrated that dystrophin is highly expressed in satellite
cells (skeletal muscle stem cells) and regulates their polarity
and asymmetric division. Hence, loss of dystrophin results not
only in myofiber fragility but also – due to strikingly reduced
asymmetric divisions – in the lack of regenerating myofibers
(Dumont et al., 2015). Farini and collaborators proposed that
PLC/IP3/IP3R/RyR1/Ca2+ signaling pathway may be activated
differently in fetal compared to adult DMD skeletal muscle fibers,
and proposed that this mechanism was directly linked to defects
in myofiber formation and to a rearrangement in the expression
of fast/slow-muscle specific genes (Farini et al., 2016).
A Developmental Role for Dystrophin
in the Heart
The role of dystrophin during human cardiac development is
still not completely deciphered. The absence of a shock absorber
that may preserve membrane homeostasis and may be involved
in several intracellular pathways is supposed to negatively affect
physiological human myocardium formation. Previous studies
reported that dystrophin is already expressed on the surface of
cardiomyocytes in 8-week-old fetuses (Chevron et al., 1994) and,
while no studies have investigated earlier phases of gestation,
some authors hypothesize that specific fetal dystrophin isoforms
may be present during early embryo development (Mora et al.,
1994). Of note, a greater quantity of dystrophin was found in
cardiac than skeletal muscle in fetuses, likely related to the earlier
development of the myocardium. In the same study, Mora and
colleagues reported that DGC proteins were expressed variably
in period between 8 and 12 weeks of gestation. The expression
of spectrin, a DGC-protein involved in the maintenance of
plasma membrane integrity and cytoskeletal structure, was
detected earlier than vinculin and talin (cytoskeletal proteins
connecting integrins), suggesting that dystrophin is probably
required on the sarcolemma before these two proteins. At
8 weeks, β-dystroglycan were found patchily on cardiac cells
and immunostaining intensity did not appear to change with
heart maturation. Adhalin (α-Sarcoglycan) did not appear in
the cardiac tissue at 8 weeks and showed limited expression
at 12 and at 16 weeks. The dystrophin-like protein utrophin
was found at 8 weeks and faintly increased from 8 to 16 weeks
(Mora et al., 1996). Finally, other authors identified a distinct
pool of dystrophin molecules associated with myofibrils and
localized within the Z-disks of the sarcomeres in association
with α-actinin and desmin, in cardiac but not in skeletal
muscle (Meng et al., 1996). Whether contractile function and
dystrophin distribution influence each other in the early stages
of development is still unknown.
HUMAN INDUCED PLURIPOTENT STEM
CELL DERIVED CARDIOMYOCYTES
AS A MODEL OF DYSTROPHIN-
ASSOCIATED CARDIOMYOPATHY
The advent of human induced pluripotent stem cells (hiPSCs) has
opened the door to the exploration of core biomedical questions
using personalized, renewable patient-specific human cell models
instead of animal models. Cardiomyocytes derived from hiPSCs
represent a unique platform to penetrate the pathophysiological
processes related to early-stage defects underlying the onset
and progression of DMD cardiomyopathy and delineate the so-
called “cellular” phenotypes. Recent validation of these cellular
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models compared to native myocardial tissue (Ronaldson-
Bouchard et al., 2018), and the possibility to increase the level
of maturation of hiPSCs using long-term cultures combined
with nanostructured surfaces that mimic the extracellular
matrix (Pioner et al., 2019a), will allow future research to
comprehensively perform complex biophysical studies to
simultaneously monitor membrane fragility, intracellular
calcium handling and myofilament function. This represents
a unique opportunity in the context of DCM, a disease rarely
requiring surgical strategies and therefore difficult to study
in vitro on human myocardial samples.
Notably, studies using patient-derived tissues often represent
the final stages of disease, therefore separating primary
mechanisms (i.e., those induced by the lack of full-length
dystrophin) from the secondary mechanisms (i.e., those induced
by chronic neurohormonal stimulation, adverse remodeling
and effects of medications) is nearly impossible. On the
other hand, small rodent models recapitulate facets of the
human cardiomyopathy phenotype at the early stages of disease
development. However, rat and mice cardiomyocytes differ
from human cells in the expression of key contractile proteins,
heart rate, electrical properties and ion channel function,
often making it difficult to translate findings to humans.
Cardiomyocytes obtained from the differentiation of iPSCs are
the most prominent model to date for modeling human heart
in vitro. Since the first report of Yamanaka and Takahashi in
2006, the reprogramming of somatic cells into embryonic-like
induced pluripotent stem cells (iPSC) has becoming a widely
used strategy for disease-in-a-dish modeling (Takahashi and
Yamanaka, 2006). Generation of iPSCs bypass ethical concerns
regarding disruption of embryos and, differently from embryonic
stem cells (ESCs), can be derived directly from patients or
healthy donors. Patient-derived iPSCs (hiPSCs) today provide
the opportunity to characterize specific disease phenotypes
in different tissues, thanks to tissue-specific differentiation
protocols. Furthermore, targeting specific genes by CRISPR-
Cas9 gene editing technology is a major resource allowing
phenotyping of any cardiomyopathy-associated mutation, as well
as a direct testing of the pathogenicity of variants of uncertain
significance (Figure 3A).
It must be emphasized that, even after differentiation
into cardiomyocytes, hiPSC-CMs retain immature features
resembling developmental cardiomyocytes. In the very early
phases (day 20–30 post differentiation), hiPSC-CMs exhibit
fetal-type proteomic patterns (van den Berg et al., 2015),
automaticity (spontaneous contraction), fetal-like ion channel
expression (Davis et al., 2011), contractile properties (Pioner
et al., 2016), and metabolism (Ulmer and Eschenhagen,
2019). A developmental-like behavior underlies the changes in
hiPSC-CM structure and function. Using conventional culture
conditions, cell growth, the organization of subcellular structures
and the improvement of cardiomyocyte function are all time-
dependent events. For instance, increase of repolarizing ion
currents (Ik1 in particular) and reduction of the funny current
(If ) decrease automaticity, together with a prolongation
of cardiomyocyte action potential (Sartiani et al., 2007).
Furthermore, sarcoplasmic reticulum calcium content becomes
more prominent in the regulation of calcium handling (Itzhaki
et al., 2006). Limited information is still available for the
contractile apparatus. Sarcomere protein composition and
isoform expression can be extremely variable in hiPSC-CMs.
In a time window of 100 days after differentiation, hiPSC-CMs
undergo sarcomere formation and isoform switch. This is similar
to the process of fetal cardiac development (Sasse et al., 1993;
Reiser et al., 2001; Racca et al., 2016), which occurs in vitro in a
time- dependent manner. Furthermore, our current knowledge
of sarcomere protein isoforms in hiPSC-CMs is limited by
the lack of any truly effective chamber-specific differentiation
protocol: for this reason, observations refer to the general
cardiomyocyte population. At thick filament level, the cardiac
fast alpha myosin heavy chain isoform (α-MHC, MHY6) and
the atrial myosin regulatory light chain (MLC-2a, MYL7) are
overall prevalent in hiPSC-CMs but long-term culture and stiff
substrates (Weber et al., 2016) drive the isoform switch toward
a predominant expression of the slow beta myosin heavy chain
isoform (β-MHC, MHY7) and of the ventricular regulatory light
chain (MLC-2v, MYL2) (Cai et al., 2019), and increase myosin
binding protein C (cMyBP-C) expression (Cai et al., 2019). Titin
(TTN) isoforms N2B and N2BA are co-expressed with a pattern
similar to that found in the heart tissue of healthy individuals
(Streckfuss-Bomeke et al., 2017). Sarcomeric protein composition
is of extreme importance when modeling hiPSC-CM for the
impact on contraction kinetics. In addition, some studies that
used CRISPR-mediated genomic deletion in WT-hiPSC-CM
lines for studying de novo sarcomere assembly reported that
β-MHC, its connection with titin (Chopra et al., 2018) and the
expression of the newly discovered Cronos titin (Zaunbrecher
et al., 2019) are necessary for sarcomere assembly and function;
non-muscle myosin II (NMM II) or α-MHC, instead, are not
required. Another fundamental sarcomeric property is the
Ca2+ buffering capacity of troponin C, which contributes to
determine the Ca2+ sensitivity (pCa50) of myofibril tension
development. Differences in thin filament protein isoform
expression or phosphorylation patterns may account for changes
in myofilament Ca2+ buffering. In hiPSC-CMs, prevalence
of slow skeletal troponin I (ssTnI, TNNI1) may recapitulate
properties typical of the embryonic age characterized by higher
myofilament Ca2+ sensitivity and lower pH sensitivity, which
may be particularly important for fetal hearts, which have modest
amounts of Ca2+ delivered to the sarcomeres and are exposed
to hypoxic conditions. As previously reported, the mechanisms
responsible for the inhibition of myofilament force generation by
acidosis include: (1) reduction in the affinity of troponin C (TnC)
for Ca2+, (2) alterations in thin filament activation, especially
the TnI-TnC interaction, and (3) inhibition of the actin-myosin
interaction (Wolska et al., 2001). Long-term culture (>90 days
after differentiation) have shown co-expression (almost 1:1)
of ssTnI with the adult cardiac troponin I isoform (cTnI)
(Bedada et al., 2014; Pioner et al., 2016). Similarly, co-expression
of slow skeletal Troponin T (ssTnT) and cardiac troponin T
(cTnT) has been reported (Iorga et al., 2017). Of note, using
the current differentiation protocols, we and other groups have
found myofibril force comparable to fetal myofibrils and kinetic
properties that more closely reflect those of adult ventricular
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FIGURE 3 | Human induced pluripotent stem cell derived cardiomyocytes. (A) Generation of hiPSCs by cell reprogramming of somatic cells from patients or healthy
donors or via CRISPR-Cas9 gene editing for the generation of isogenic pairs. (B) Current maturation strategies for hiPSC-CMs at cell level (2D strategies) or in
multicellular model (3D strategies). (C) Possible methods for the assessment of electrophysiological and contractile properties.
myofibrils expressing β MHC (Pioner et al., 2016; Racca et al.,
2016; Iorga et al., 2017).
For this reason, maturation strategies applied to hiPSC-
CMs are a primary challenge in the field. In the last few
years, many researchers have explored ways to induce greater
structure and function development of hiPSC-CMs, using a
wide range of methods such as long-term culture (Lundy et al.,
2013), biomimetic substrates (Macadangdang et al., 2014, 2015;
Ribeiro et al., 2015), electrical or mechanical stimulation (Nunes
et al., 2013), co-culture with other cell types (Tulloch et al.,
2011), alteration of growth media (Birket et al., 2015) and 3D
culture system such as engineered heart tissue (EHTs), heart
on a chip or even in vivo neonatal rat heart system (Cho
et al., 2017; Figure 3B). Since hiPSC-CMs possess features of
developing cardiomyocytes, they can serve as human models
for investigating the developmental time-course of early-stage
cardiac diseases at cardiac cell level (Figure 3C).
Modeling Early-Stages of DMD-
Associated DCM Using hiPSC-CMs
Cardiomyocytes derived from patient-hiPSCs can be considered
a unique platform to address early-stage defects underlying
DMD cardiomyopathy in a developing human heart. Models
for inherited DCM have been obtained for mutated genes
involving sarcomere and sarcomere Z-band stability, E-C
coupling proteins, cytoskeleton, mitochondria and desmosomes
(Table 1). Models for relatively common (arrhytmogenic right
ventricular cardiomyopathies, laminopathies) as well as rare
genetic syndromes associated with DCM (Friedreich’s ataxia,
Barth syndrome, carnitine palmitoyltransferase II deficiency,
LEOPARD syndrome, Pompe disease) have been reported
(Burridge et al., 2016). Many studies using hiPSCs sought
to mirror the pathomechanisms found in end-stage human
samples or animal models, although none addressed in-depth the
potential for novel therapeutic targets. Patient-derived hiPSC-
cardiomyocytes and genome editing of DMD via CRISPR-
Cas9 or TALEN can provide direct evidence that the lack of
dystrophin directly impacts cardiomyocyte function. In normal
hiPSC-CMs, full-length dystrophin (Dp427) is expressed early
after differentiation. Recently, mass spectroscopy analysis has
suggested that dystrophin is upregulated in a period of time
from days 30 to 60 post differentiation. This is also supported
by similar results in the developmental expression pattern of
embryonic and postnatal mouse hearts (Cai et al., 2019). A lack
of information limits the comprehension of the physiological
role and expression levels of the Dp71 isoform and of utrophin.
However, a novel transient dystrophin isoform (Dp412 kDa) was
identified in hiPSCs during mesodermal differentiation induced
by a 72 h exposure to bone morphogenetic protein 4 (BMP4),
suggesting a role of shorter isoforms during development
(Massourides et al., 2015). Furthermore, Jelinkova et al. (2019)
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tested a WT hiPSC and two WT hESC lines and reported
that Dp427 is already expressed before differentiation and that
the absence of dystrophin leads to increased ROS production,
NOS activity and DNA damage in DMD-hiPSCs (2 independent
patients). These results further support the value of the hiPSC
platform for modeling early-stages of DMD.
In such perspective, we have summarized the major
findings and limitations of published DMD-hiPSC-CMs models
in Table 2.
Excitation Contraction Coupling of
DMD-hiPSC Cardiomyocyte Models
Calcium handling abnormalities have been described as a major
consequence of dystrophin and other DCM-related mutations
but the mechanistic progression remains unclear. A study
from the Wu laboratory explored DCM-patient derived cell
lines carrying the R173W-cTnT mutation, reporting reduced
sarcoplasmic reticulum calcium content and higher rate of
spontaneous arrhythmic electrical activity compared to normal
cardiomyocytes (Sun et al., 2012). In this mutant cell line,
decreased cell contractility was determined by atomic force
microscopy and compared with lines obtained from the non-
affected members of the same family. Overexpression of the
sarcoplasmic reticulum Ca2+ adenosine triphosphatase (Serca2a)
enhanced the intracellular Ca2+ transient and restored force
production (Sun et al., 2012). These and other works have
provided reports of stem cell lines with DCM-associated
mutations including RBM20 (Wyles et al., 2016a), PLB
(Karakikes et al., 2015), EMD (Shimojima et al., 2017), or CSRP3
(Li et al., 2019), showing marked calcium handling abnormalities
that may recapitulate the early myocardial alterations occurring
in human DCM hearts. However, the underlying molecular
mechanisms of myocardial dysfunction and damage in the
presence of DCM-related mutations in various genes can be
completely different despite the common final phenotype.
For DMD, two main hypotheses have been advanced: (1)
membrane fragility or damage leading to membrane tear or
rupture that facilitates abnormal calcium influx, as indirectly
demonstrated by treating DMD cells with membrane sealants
(i.e., Polaxamer 188) (Yasuda et al., 2005); (2) altered ion channel
function and dysregulation of calcium homeostasis as a direct
consequence of the altered dystrophin complex (Zhan et al.,
2014). Guan and collaborators generated cardiomyocytes derived
from the urine of a dystrophin-mutant DMD patient with a
deletion of exon 50 (DMD-1 exon 50), resulting in a dystrophin-
deficient phenotype. DMD-1exon50 displayed unique features
such as increased membrane susceptibility to hypotonic stress,
slower Ca2+ transients in the early phases after differentiation
and increased probability of mitochondrial permeability pore
opening (Guan et al., 2014). Similarly, DMD cell lines with
deletion of exons 49–50 (DMD-1 exons 49–50) overexpressed
the immunoproteasome subunits, while their inhibition by ONX-
0914 (proteasome inhibitor) reduced the sarcolemmal damage, as
indicated by decreased release of cTnI and TNF-α after treatment
(Farini et al., 2019). Lin and collaborators described hiPSC-CM
cell lines from two patients carrying out-of-frame deletion in
DMD exons 45–52 (DMD-1 exons 45–52). They reported DMD-
CMs with profound reduction of the L-type calcium current and
increased cytosolic Ca2+ levels, and identified a downstream
activation DIABLO-CASP3 that was related to mitochondrial
apoptosis (Hinson et al., 2015). This mechanism is in keeping
with the increased reactive oxygen species (ROS) levels found in
DMD-CM models (Gartz et al., 2018; Jelinkova et al., 2019). The
membrane sealant P188 (Polaxamer 188) was able to normalize
the increased diastolic calcium levels and to revert the increase in
the rate of apoptosis, supporting the hypothesis that membrane
damage/fragility leads to intracellular calcium overload even
in the early stages of myocardial differentiation (Lin et al.,
2015). A unifying hypothesis may involve mechanosensitive
channels, e.g., the transient receptor potential canonical channel
1 (TRPC1), which transduce membrane stretch into a cationic
(Na+, K+, Ca2+, and Mg2+) flux across the sarcolemma, and
may be gated by an excessive tension developed within the
lipid bilayer, as previously reviewed (Maroto et al., 2005). In
support of this idea, a recent test exposed DMD (DMD-1 exons
43–45) and control hiPSC-CMs, plated on a fibronectin-coated
silicon chamber, to a periodical mechanical stretching (120%
elongation) at a frequency of 60 cycles per min and measured the
response of intracellular calcium levels after 3 h (Tsurumi et al.,
2019). A short-term mechanical stretch protocol was sufficient to
increase diastolic calcium levels and calcium transient amplitude
in DMD cells while it did not cause such effects in controls.
However, these studies are limited by the small number of cell
lines and by the use of immature cardiomyocytes in the early-
phases of cardiac differentiation and maturation. We recently
reported the analysis of calcium transients in hiPSC-CMs at
day 100 of differentiation, comparing the DMD-1 Exon 50
line to a healthy control and its CRISPR-Cas9 genome edited
isogenic control (Exon 1 deletion in the DMD gene, DMD-
c.263delG) (Pioner et al., 2019a; Figure 4). At this advanced
stage of differentiation and maturation, hiPSC-CMs paced by
field stimulation showed adaptation to frequency changes. DMD-
1 Exon 50 showed slower calcium transient rise and decay
compared to controls, and these changes were comparable to
those observed in our CRISPR-Cas9 generated cell line (DMD-
c.263delG) expressing a shorter synthetic dystrophin. Slower
duration of calcium transients is an alteration found in other
DMD cell lines (Figure 4C). Both cell lines were associated with
prolonged cardiomyocyte relaxation at low loading conditions
(Figure 4D). This directly demonstrated that the lack of the full-
length dystrophin is sufficient to perturb normal contractility of
cardiomyocytes, with abnormal calcium homeostasis as a leading
consequence. Moreover, another recent study generated a cell line
from a male patient (DMD- c.5899C > T) and from a DMD
female carrier (1 Exons 8–12). Interestingly, both DMD cell
lines showed prolonged action potential (AP) duration compared
to control lines, and those measured in cells from the female
carrier were even larger (APD90, 600 vs. 400 ms in the male
patient). The prolongation of APs was attributed to an increase of
L-type calcium (ICa−L) peak current amplitude and CACNA1C
expression (ICa−L main channel subunit), which were even more
evident in the iPSC-CMs obtained from the female carrier.
Regulation or expression of ion channels might be dependent

























TABLE 2 | DMD-cardiomyopathy studies based on hiPSC-CMs: individual mutations vs. functional parameter and therapeutic attempts in vitro.
Mutation/
parameter
















Guan et al., 2014;
Macadangdang
et al., 2015; Pioner
et al., 2019a
















Nanni et al., 2016















Lin et al., 2015







et al., 2015; Pioner
et al., 2019a




1 Exons 43–45 ↑Stretch-induced
intracellular calcium
entry
Tsurumi et al., 2019
1 Exons 8–12 ↑ICa−L density;
prolonged APD
Eisen et al., 2019
c.5899C > T ↑ICa−L density;
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Eisen et al., 2019




























































TABLE 2 | Continued
Mutation/
parameter





1 Exons 45–50 ↑Spontaneous
electrical activity
Caluori et al., 2019
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1 Exons 46–55 Fragility/damage Cellular arrhythmias Exon 45 skipping
with PMO improved
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1 Exon 44 CRISPR-Cas9
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Long et al., 2018
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FIGURE 4 | Morphology and function altered in DMD-hiPSC-CMs from patient confirmed in a CRISPR-Cas9 gene edited cell line. Original data are modified from
Pioner et al. (2019b) with the correct permission from the owner (Pioner et al., 2019a). A DMD-hiPSC-cell line from a patient (with 1 Exon 50 in DMD gene) and a
CRISPR-Cas9 gene edited cell line (c.263 1G) targeting Exon 1 in healthy control cell line (Control) were generated and the cardiomyocytes were matured onto
nanotopographic cues for 3 months. (A) DMD-hiPSC-CMs displayed aspect ratio similar to adult cardiomyocytes and Z-bands were observed across the entire cell
width (diameter), suggesting DMD-CMs experienced hypertrophy and a greater number of myofibrils in parallel. (B) Despite similar myofibril alignment to
control-hiPSC-CMs, sarcomere diameters (estimated from the length of Z-bands by transmitted electron microscopy) were significantly smaller, suggesting a
possible reduction in the parallel assembly of myofilaments within individual myofibrils. (C) Meta-analysis on Calcium transient duration. (D) Representative traces of
calcium transients (CaT), cell shortening and myofibril mechanics of DMD-hiPSC-CMs compared to controls. Simultaneous recordings at single cell level revealed
slower CaT decay (estimated from time to peak to 50% of CaT decay, RT50, ms), slower cell relaxation (RT50, ms) at 37◦C and external pacing (0.5 Hz reported).
Compared to other studies reporting similar analysis of calcium transients, slower CaT duration might be a peculiarity of DMD-hiPSC-CMs. Single myofibrils showed
lower isometric-tension generating capacity and slower myofibril relaxation (slow tREL and fast kREL). This study concluded that both calcium handling and myofibril
abnormalities may contribute to prolong cell relaxation.
on the specific protein defects rather than on the common
downstream pathways related to cell degeneration toward a
DCM phenotype. For instance, another DCM-hiPSC model
was obtained from patients harboring a fukutin-related protein
gene mutation (826C > A; Leu276Ile, transmembrane protein)
associated to Limb-Girdle muscular dystrophy (LGMD) and was
studied at comparable levels of maturation. In this case, the
authors reported DCM-hiPSC-CMs with reduced AP amplitude
and shorter AP duration compared to healthy controls, with
reduced peak and late Na currents (INa), as well as lower peak
L-type calcium channel current; these changes were likely related
to the reduced expression of their related genes, SCN5A and
CACNA1C. In addition, the rapidly activating delayed rectifier
potassium current (IKr) was reduced, whereas the transient
outward current (Ito) and slowly activating delayed-rectifier
potassium current (IKs) were similar in DCM and control
cardiomyocytes (El-Battrawy et al., 2018).
Force and Contractile Properties of
DMD-hiPSC Cardiomyocyte Models
The N-terminal domain of dystrophin has homology for
cytoskeletal F-actin and interacts in the context of costamere
domains that couple sarcolemma to sarcomeric Z-bands. As
cardiac cells rapidly shorten during contraction, electrostatic
interaction between the basic spectrin repeats and actin filaments
serve to dampen elastic extension during stretch (Ervasti, 2007).
In this context, a complex network involves multiple DCM-
related proteins including the sarcomere proteins titin (TTN),
β-myosin heavy chain (β-MHC), cTnT, cTnI, cTnC, tropomyosin
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cardiac troponin I (cTnI)–interacting kinase (TNNI3K) and
other Z-band interacting proteins such as α-actinin, desmin,
telethonin, cardiac ankyrin repeat protein, nebulette, α-B-
crystallin and cipher. The Z-band complex seems to be
involved in the mechanosensory mechanisms that convert
mechanical stimuli into biochemical signals, and dystrophin has
connections with several Z-band proteins. Consequently, DMD-
with 1exon50 displayed less adaptiveness to variations of the
topographical cues (cell and sarcomere alignment), which was
related to reduced actin turnover, as studied by fluorescence
recovery after photobleaching (FRAP). This behavior was
reproduced in a DMD CRISPR-Cas9 gene-edited cell line
(Macadangdang et al., 2015). By comparison, hiPSC-CMs with a
mutation in the RBM20 gene exhibited heterogeneous sarcomeric
organization patterns. RBM20-engineered heart tissues (EHTs)
showed impaired force of contraction and increased passive
tension that was associated to a lower degree of the switch from
the N2BA to the N2B isoform of titin, as a consequence of
the S635A RBM20 mutation impacting on RNA splicing and
transcription (Streckfuss-Bomeke et al., 2017). In a different way,
loss of dystrophin may impact both cytoskeletal F-actin and
sarcomeric actin in cardiomyocytes.
Myofibrils are the most abundant organelles of adult
cardiomyocytes, occupying approximately 50–60% of the
cytoplasmic volume. However, myofibrils are less represented
in the contractile machinery of hiPSC-CMs, in which the
sarcomere bands and lines gradually form in the advanced
stages of maturation (Gherghiceanu et al., 2011). In this context,
we investigated whether loss of dystrophin may affect the
contractile properties at single myofibril level by applying a cell
skinning protocol followed by tissue homogenizationto obtain
single myofibrils, which were studied using a custom-made
force-recording apparatus with fast solution switching, as
previously described (Pioner et al., 2016). We found reduced
tension production upon Ca-mediated activation in DMD
myofibrils, as compared to controls. However, the kinetics
of force development (kACT) and relaxation (slow kREL) after
calcium removal were not different, suggesting no changes in
the rate of crossbridge cycling during tension development and
detachment. Also, we found a slower fast phase of relaxation
(fast kREL), which is mainly regulated by inter-sarcomere
dynamics (Pioner et al., 2019a; Figure 4D), paralleled by a slower
contraction (shortening) of intact cells (Figure 4B). Altered
myofibril contractile function could be related to developmental
alterations, although the mechanism is not clear (Figure 4A).
This should encourage future studies to better define the
fundamental role of sarcomere protein composition for the
definition of contractile properties. Another group investigated
mutations in the dystrophin actin-binding domain (ABD1)
causing truncated forms of dystrophin (DMD- 1 Exon 3–9, 6–9,
or 7–11). Force measurements using multicellular preparations
(engineered heart muscle, EHM) displayed lower force in
DMD-mutant cell lines and the de novo insertion of the missing
exon using CRISPR-Cas9 technology only partially restored
the contractile performance. Among other DCM models, the
hiPSC-CMs with absence/reduction of full-length dystrophin
may contribute to evaluate the functional consequences of
dystrophin loss and elucidate the role of a variety of proteins
interacting around the N-terminal of full-length dystrophin,





To date, the possibility of using hiPSC-CMs to predict individual
prognosis or response to therapies is limited by lack of direct
validations, that is, patient-specific hiPSC-CMs have never been
tested against actual adult cardiomyocytes from the same patient
or from patients with a similar condition. This is due to
the poor availability of human samples from patients with
cardiomyopathies or other arrhythmogenic conditions, and the
limited experience of many research centers in investigating
fresh human myocardium and cardiomyocytes (Tardiff et al.,
2015). We have recently developed a technique (Coppini et al.,
2014) to isolate single ventricular cardiomyocytes and trabecule
from the surgical samples of obstructive HCM patients. We
were therefore able to study adult CMs in order to characterize
the functional abnormalities of action potentials, ion currents,
Ca2+ handling, myocardial contraction and relaxation, and
test the effectiveness of different ion channel blockers such
as ranolazine or disopyramide (Coppini et al., 2013; Coppini
et al., 2018; Ferrantini et al., 2018). In Pioner et al. (2019b),
we compared the physiological properties of iPSC-CMs from an
healthy donor, differentiated using nanopatterned surfaces and
long-term cultures, with those of adult cardiomyocytes from non-
failing non-hypertrophic surgical patients (Pioner et al., 2019b).
In terms of action potential shape and duration, calcium transient
properties and response to β-adrenergic agonists, hiPSC-CMs
at an advanced degree of maturation closely approximated the
features of freshly isolated human adult cardiomyocytes (Pioner
et al., 2019b). While obtaining fresh cardiac samples from DMD
patients is hardly feasible, our technique can be developed
to allow the isolation of cardiomyocytes from intramyocardial
biopsies, to be used for functional studies in selected patients,
allowing a direct comparison with individual hiPSC-CMs.
Moreover, in order to improve hiPSC-CM maturation, single
cardiomyocytes or 3D cultures (engineered heart tissues; Gupta
et al., 2018) could be challenged during maturation using
electrical stimulation at different pacing rates and periodic
stretch-release protocols, simulating the contraction-relaxation
cycle of the native heart (Sun and Nunes, 2017; Ronaldson-
Bouchard et al., 2019). Such approach to cardiomyocyte
differentiation might be easily achieved using smart contractile
materials as culture substrates, such as liquid-crystal elastomer,
which we recently developed and characterized (Martella et al.,
2017; Ferrantini et al., 2019).
The possibility offered by hiPSC-CMs to identify patient-
or mutation-specific mechanisms of disease and test novel
therapies in a personalized manner is hampered by the fact that
current approaches are extremely costly and time consuming.
The development of rapid high-throughput assays to study the
pathophysiological features of different hiPSC-CM lines and
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test novel therapeutic approaches is therefore warranted. We
recently developed a system to simultaneously record action
potentials and intracellular Ca2+ from multiple iPSC-CMs using
a fast camera, paralleled by a streamlined data analysis system
to rapidly extract the main functional biomarkers from each
recording (Pioner et al., 2019b). In an attempt to further improve
the throughput of cell-line analysis, a possible approach would
be an all-optical semi-automatic platform combining the parallel
detection of multiple functional properties with electrode-free
optogenetic control of electrical function in the sample. This
approach would be feasible using genetically encoded voltage
indicators (GEVIs) or calcium indicators (GECIs) (Kaestner et al.,
2014; Huebsch et al., 2015; Shaheen et al., 2018) and gene-
encoded actuators (channelrhodopsin) (Klimas et al., 2016). Such
comprehensive platform, when combined with a semi-automated
experimental-control and analysis system (Klimas et al., 2016),
will allow repeatable longitudinal prolonged evaluations of iPSC-
CMs at different time points and facilitate the evaluation of
their response to different treatments. In addition to these
technologies, CRISPR-Cas9 gene repair was recently improved
by the newly discovered CRISPR-Cpf1 nuclease (Zhang et al.,
2017). CRISPR-Cpf1 is driven by a single RNA guide (gRNA)
and prefers T-rich protospacer adjacent motif (PAM) sequences:
this feature is important for the potential correction of other
disease-related mutations, because not all mutation sites contain
G-rich PAM sequences for SpCas9 or PAMs for other Cas9
orthologs. Importantly, Cpf1 is about 140 amminoacids smaller
than the most widely used SpCas9, which can potentially
enhance the packaging and delivery by adenovirus, adeno-
associated (AAV) or other viral constructs. Finally, Cpf1 can
be used to permanently correct DMD mutations, restoring
dystrophin expression and efficiently preventing the progression
of the disease, as reported in DMD patient-derived iPSCs
and mdx mice. The combination of biophysical approaches
with the breakthrough of increasingly precise genome editing
techniques may pave the way to a truly personalized medicine
for DMD patients.
TRANSLATING STEM CELL MODELING
FROM BENCH TO BED SIDE
Four groups of molecules are currently in use in the clinical
management of patients with DMD cardiomyopathy: renin-
angiotensin-inhibiting agents, beta-adrenergic receptor blockers,
mineralocorticoid receptor antagonists and corticosteroids.
Although useful for symptom management, none of these
molecules is capable of modifying the natural history of the
disease. Currently, none of the stem cell-based studies have
reported or suggested novel pharmacological approaches for
dystrophin-associated cardiomyopathies. Few pilot tests on
animal models were attempted, using a membrane sealant
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(Lin et al., 2015) or an immunoproteasome inhibitor (Farini et al.,
2019), but these agents are not currently under development
for use in patients. In other DCM models, a limited number
of disease modifying therapeutic approaches were attempted,
including the overexpression of Serca2a by viral-vector gene-
therapy (Sun et al., 2012), and the modulation of SERCA/PLN
through the mechanoreceptor protein integrin-linked kinase
(ILK) (Traister et al., 2014). Indeed, most of the DCM hiPSC
studies sought to identify novel mechanistic targets and were only
labeled as a promising platform for a pharmacological therapy,
but never used for an actual pharmacological validation. This is
undoubtedly related to the immaturity of hiPSC-CM models and
the fact that findings obtained using in vitro models cannot be so
easily translated into trials in vivo.
In recent years, potentially curative approaches for DMD
have begun to take shape. Unlike small molecule treatments,
CRISPR-Cas9 or TALEN gene-targeted therapies are designed
with the goal to induce expression of a functional gene product
that will reestablish normal myocyte physiology. Since these
therapies aim to repair the original defect in the cell by restoring
functional dystrophin expression, their success is less dependent
upon identifying the exact molecular consequences of the lack
of dystrophin. As shown in Table 3, major efforts involved the
use CRISPR-Cas9 in the design of mutation-specific therapies,
which include exon skipping, reframe or deletion of portions
in the DMD gene. Notably, successful restoration of contractile
function was observed in a large group of hiPSC models carrying
mutations in the ABD domain (mostly linked to BMD) or in
the central domains (mostly associated to DMD) (Kyrychenko
et al., 2017; Zhang et al., 2017; Long et al., 2018; Min et al.,
2019). For this purpose, more effort should be moved toward the
generation of BMD-patient cell lines (Gowran et al., 2018), as this
patient group frequently diagnosed mid-life and is definitely an
understudied group. In addition, BMD patients appear to be the
most promising candidates for autologous cell transplantation
as well as for in vitro studies aimed at identifying specific,
novel targets that emerge in the presence of semi-functional
truncated dystrophin proteins. Current strategies still lack the
ability to obtain a lasting and efficient correction of the primary
defect. In addition, DMD and BMD are associated with a variety
of different mutations in the DMD gene. Therefore, a host
of different therapeutic approaches are required for different
patient subgroups, depending on the site and nature of their
mutation. For instance, PTC124 (Ataluren) has been used in
Europe to treat DMD patients carrying nonsense mutations
(10% of total variants; Bladen et al., 2015). PTC124 renders
ribosomes less sensitive to premature stop codons by promoting
insertion of near-cognate tRNA at the site of nonsense codons
with no apparent effects on downstream transcription, mRNA
processing, or stability of the resulting protein, thereby allowing
the production of functional dystrophin proteins. Ataluren
works particularly well for the stop codon “UGA” (Welch
et al., 2007). For this reason, the drug could be eligible for
preclinical personalized tests on patient-specific stem cell-based
models, which have been rarely attempted so far (Koopmann
et al., 2012; Lee et al., 2017). Finally, innovative therapeutic
approaches may consider repositioning drugs in use for other
conditions or strategies acting on molecular factors that induce or
downregulate common molecular pathways involved in genetic
cardiomyopathies. Although such “universal” approaches will
not restore dystrophin expression in the heart, they could still
delay disease progression, be well tolerated, and be appropriate
for a broader range of patients with DMD.
CONCLUSION
In this review, we analyzed the current insights of DMD-
associated cardiomyopathy, from the clinical aspects to
innovative disease modeling based on human iPSC derived
cardiomyocytes, in the attempt to decipher specific mechanisms
underlying DCM pathogenesis in DMD patients. Human models
of iPSC-cardiomyocytes are a viable cell-based platform for
investigating the human cardiac phenotype resulting from
specific gene mutations. These models can recapitulate the facets
of the physiology and pathophysiology of native cardiomyocytes,
opening new opportunities for research. hiPSC-cardiomyocytes
allow the study of unique individual patients without reliance
on isogenic strains of animals and avoiding invasive biopsies of
human cardiac tissue samples. Their progressive maturation of
their cardiac phenotype, obtained with advanced differentiation
techniques, is a powerful tool for investigating the early-stage
consequences of dystrophin mutations that DMD, and their
effects on cardiac development. Existing studies suggest that the
pathogenic mechanisms appear early in the disease progression
as a combination of the developmental consequences of the
absence of full-length dystrophin (Dp427) in cardiomyocytes.
Gene therapy with micro dystrophin, up-regulation of utrophin
or exon skipping approaches are currently the most promising
ways to rescue or at least mitigate the DMD phenotype. For
this reason, despite the obvious limitations related mostly to
their immature phenotype, the advent of hiPSC-cardiomyocytes
presents a unique opportunity to improve our approach to the
understanding of the pathophysiology of DMD cardiomyopathy.
AUTHOR CONTRIBUTIONS
JP, AF, and CF contributed to the design and wrote the
manuscript in consultation with RC, LS, MD, SF, CP, and IO.
JP and NC performed the meta-analysis and prepared figures
and tables. All authors critically reviewed the manuscript and
declared that the research was conducted in the absence of any
commercial or financial relationships that could be construed as
a potential conflict of interest.
FUNDING
This work was supported by Fondazione Telethon Italy
(GGP16191), Fondazione Telethon-UILDM (GUP19012),
777204/Horizon 2020 (SILICO-FCM project).
Frontiers in Physiology | www.frontiersin.org 17 May 2020 | Volume 11 | Article 368
fphys-11-00368 May 10, 2020 Time: 19:26 # 18
Pioner et al. Impact of DMD-Stem Cell Modeling on DCM
REFERENCES
Ader, F., De Groote, P., Réant, P., Rooryck-Thambo, C., Dupin-Deguine, D.,
Rambaud, C., et al. (2019). FLNC pathogenic variants in patients with
cardiomyopathies: prevalence and genotype-phenotype correlations. Clin.
Genet. 96, 317–329. doi: 10.1111/cge.13594
Bedada, F. B., Chan, S. S., Metzger, S. K., Zhang, L., Zhang, J., Garry, D. J., et al.
(2014). Acquisition of a quantitative, stoichiometrically conserved ratiometric
marker of maturation status in stem cell-derived cardiac myocytes. Stem Cell
Rep. 3, 594–605. doi: 10.1016/j.stemcr.2014.07.012
Bertero A, Fields PA, Smith AST, Leonard A, Beussman K, Sniadecki NJ, et al.
(2019). Chromatin compartment dynamics in a haploinsufficient model of
cardiac laminopathy. J. Cell Biol. 218, 2919–2944. doi: 10.1083/jcb.201902117
Birket MJ, Ribeiro MC, Kosmidis G, Ward D, Leitoguinho AR, van de Pol V,
et al. (2015). Contractile defect caused by mutation in MYBPC3 revealed under
conditions optimized for human PSC-Cardiomyocyte function. Cell Rep. 13,
733–745. doi: 10.1016/j.celrep.2015.09.025
Bladen, C. L., Salgado, D., Monges, S., Foncuberta, M. E., Kekou, K., and Kosma,
K. (2015). The TREAT-NMD DMD global database: analysis of more than
7,000 duchenne muscular dystrophy mutations. Hum Mutat. 36, 395–402. doi:
10.1002/humu.22758
Blake, D. J., Tinsley, J. M., and Davies, K. E. (1996). Utrophin: a structural and
functional comparison to dystrophin. Brain Pathol. 6, 37–47.
Bondue, A., Arbustini, E., Bianco, A., Ciccarelli, M., Dawson, D., De Rosa M., et al.
(2018). Complex roads from genotype to phenotype in dilated cardiomyopathy:
scientific update from the working group of myocardial function Of The
European Society Of cardiology. Cardiovascu. Rese 114, 1287–1303.
Broughton, K. M., Li, J., Sarmah, E., Warren, C. M., Lin, Y. H., Henze, M. P., et al.
(2016). A myosin activator improves actin assembly and sarcomere function of
human-induced pluripotent stem cell-derived cardiomyocytes with a troponin
T point mutation. Am. J Physiol Heart Circ. Physiol. 311, H107–H117. doi:
10.1152/ajpheart.00162.2016
Burridge, P. W., Diecke, S., Matsa, E., Sharma, A., Wu, H., and Wu, J. C. (2016).
Modeling cardiovascular diseases with patient-specific human pluripotent stem
cell-derived cardiomyocytes. Methods Mol. Biol. 1353, 119–130.
Cai W, Zhang J, de Lange WJ, Gregorich ZR, Karp H, Farrell ET, et al. (2019). an
unbiased proteomics method to assess the maturation of human pluripotent
stem cell-derived cardiomyocytes. Circ. Res. 125, 936–953. doi: 10.1161/
CIRCRESAHA.119.315305
Caluori, G., Pribyl, J., Pesl, M., Jelinkova, S., Rotrekl, V., Skladal, P., et al.
(2019). Non-invasive electromechanical cell-based biosensors for improved
investigation of 3D cardiac models. Biosens. Bioelectr. 125, 129–135. doi: 10.
1016/j.bios.2018.10.021
Campbell, M. D., Witcher, M., Gopal, A., and Michele, D. E. (2016). Dilated
cardiomyopathy mutations in delta-sarcoglycan exert a dominant-negative
effect on cardiac myocyte mechanical stability. Am. J. Physiol Heart Circ.
Physiol. 310, H1140–H1150. doi: 10.1152/ajpheart.00521.2015
Capetanaki, Y., Papathanasiou, S., Diokmetzidou, A., Vatsellas, G., and Tsikitis, M.,
(2015). Desmin related disease: a matter of cell survival failure. Curr. Opin. Cell
Biol. 32, 113–120. doi: 10.1016/j.ceb.2015.01.004
Ceholski, D. K., Turnbull, I. C., Kong, C. W., Koplev, S., Mayourian, J., Gorski,
P. A., et al. (2018). Functional and transcriptomic insights into pathogenesis
of R9C phospholamban mutation using human induced pluripotent stem cell-
derived cardiomyocytes. J. Mol. Cell. Cardiol. 119, 147–154. doi: 10.1016/j.
yjmcc.2018.05.007
Chang, A. C. Y., Chang, A. C. H., Kirillova, A., Sasagawa, K., Su, W., Weber, G.,
et al. (2018). Telomere shortening is a hallmark of genetic cardiomyopathies.
Proc. Nat;l. Acad. Sci. U.S.A 115, 9276–9281.
Chevron, M. P., Girard, F., Claustres, M., and Demaille, J. (1994). Expression and
subcellular localization of dystrophin in skeletal, cardiac and smooth muscles
during the human development. Neuromusc. Disord. 4, 419–432.
Cho, G. S., Tampakakis, E., Andersen, P., and Kwon, C., (2017). Use of a neonatal
rat system as a bioincubator to generate adult-like mature cardiomyocytes
from human and mouse pluripotent stem cells. Nat. Protoc. 12, 2097–2109.
doi: 10.1038/nprot.2017.089
Chopra, A., Kutys, M. L., Zhang, K., Polacheck, W. J., Sheng, C. C., Luu, R. J., et al.
(2018). Force generation via beta-cardiac myosin, titin, and alpha-actinin drives
cardiac sarcomere assembly from cell-matrix adhesions. Dev. Cell 44, 87.e5–96
e5. doi: 10.1016/j.devcel.2017.12.012
Coppini, R., Ferrantin, C., Aiazzi, A., Mazzoni, L., Sartianiet, L., Mugelli, A.,
et al. (2014). Isolation and functional characterization of human ventricular
cardiomyocytes from fresh surgical samples. J. Visual. Exp. 86:e51116. doi:
10.3791/51116
Coppini, R., Ferrantini, C., Mugelli, A., Poggesi, C., and Cerbai, E. (2018). Altered
Ca(2+) and Na(+) homeostasis in human hypertrophic cardiomyopathy:
implications for arrhythmogenesis. Front. Physiol. 9:1391. doi: 10.3389/fphys.
2018.01391
Coppini, R., Ferrantini, C., Yao, L., Fan, P., Del Lungo, M., and Stillitano, F.
(2013). Late sodium current inhibition reverses electromechanical dysfunction
in human hypertrophic cardiomyopathy. Circulation 127, 575–584. doi: 10.
1161/CIRCULATIONAHA.112.134932
Corrado, G., Lissoni, A., Beretta, S., Terenghi, L., Tadeo, G., and Foglia-Manzillo,
G. (2002). Prognostic value of electrocardiograms, ventricular late potentials,
ventricular arrhythmias, and left ventricular systolic dysfunction in patients
with duchenne muscular dystrophy. Am. J. Cardiol. 89, 838–841.
Davis, RP, van den Berg, CW, Casini S, Braam, S. R, Mummery, C. L. et al. (2011).
Pluripotent stem cell models of cardiac disease and their implication for drug
discovery and development. Trends Mol. Med. 17, 475–484. doi: 10.1016/j.
molmed.2011.05.001
DeWitt, M. M., MacLeod, H. M., Soliven, B., and McNally, E. M. (2006).
Phospholamban R14 deletion results in late-onset, mild, hereditary dilated
cardiomyopathy. J. Am. Col. Cardiol. 48, 1396–1398.
Dick, E., Kalra, S., Anderson, D., George, V., Ritso, M., and Laval, S. H. (2013). Exon
skipping and gene transfer restore dystrophin expression in human induced
pluripotent stem cells-cardiomyocytes harboring DMD mutations. Stem Cells
Dev. 22, 2714–2724. doi: 10.1089/scd.2013.0135
Dumont, N. A., Wang, Y. X., von Maltzahn, J., Pasut, A., Bentzinger, C. F., Brun,
C. E., et al. (2015). Dystrophin expression in muscle stem cells regulates their
polarity and asymmetric division. Nat. Med. 21, 1455–1463. doi: 10.1038/nm.
3990
Eagle, M., Baudouin, S. V., Chandler, C., Giddings, D. R., Bullock, R., and
Bushby, K. (2002). Survival in Duchenne muscular dystrophy: improvements
in life expectancy since 1967 and the impact of home nocturnal ventilation.
Neuromusc. Disord. 12, 926–929.
Eisen, B., Ben Jehuda, R., Cuttitta, A. J., Mekies, L. N., Shemer, Y., and Baskin,
P. (2019). Electrophysiological abnormalities in induced pluripotent stem
cell-derived cardiomyocytes generated from duchenne muscular dystrophy
patients. J. Cell. Mol. Med. 23, 2125–2135. doi: 10.1111/jcmm.14124
El-Battrawy, I., Zhao, Z., Lan, H., Li, X., Yücel, G., Lang, S., et al. (2018).
Ion channel dysfunctions in dilated cardiomyopathy in limb-girdle muscular
dystrophy.Circ.. Genomic Precis. Med. 11:e001893. doi: 10.1161/CIRCGEN.117.
001893
Ervasti, J. M. (2003). Costameres: the achillesl heel of herculean muscle. J. Biol.
Chem. 278, 13591–13594.
Ervasti, J. M. (2007). Dystrophin, its interactions with other proteins, and
implications for muscular dystrophy. Biochim. Biophys. Acta 1772, 108–117.
Ervasti, J. M., and Campbell, K. P. (1993). A role for the dystrophin-glycoprotein
complex as a transmembrane linker between laminin and actin. J. Cell Biol. 122,
809–823.
Farini, A., Gowran, A., Bella, P., Sitzia, C., Scopece, A., Castiglioni, E., et al.
(2019). Fibrosis rescue improves cardiac function in dystrophin-deficient mice
and duchenne patient-specific cardiomyocytes by immunoproteasome
modulation. Am. J. Pathol. 189, 339–353. doi: 10.1016/j.ajpath.2018.
10.010
Farini, A., Sitzia, C., Cassinelli, L., Colleoni, F., Parolini, D., and Giovanella,
U. (2016). Inositol 1,4,5-trisphosphate (IP3)-dependent Ca2+ signaling
mediates delayed myogenesis in Duchenne muscular dystrophy fetal muscle.
Development 143, 658–669. doi: 10.1242/dev.126193
Fayssoil, A., Abasse, S., and Silverston, K. (2017). Cardiac Involvement
classification and therapeutic management in patients with duchenne muscular
dystrophy. J. Neuromusc. Dis. 4, 17–23. doi: 10.3233/JND-160194
Fayssoil, A., Orlikowski, D., Nardi, O., and Annane, D. (2008). Complete
atrioventricular block in duchenne muscular dystrophy. Eur. Eur. Pacing,
ArrhythmiasCardiac Electrophysiol. 10, 1351–1352.
Frontiers in Physiology | www.frontiersin.org 18 May 2020 | Volume 11 | Article 368
fphys-11-00368 May 10, 2020 Time: 19:26 # 19
Pioner et al. Impact of DMD-Stem Cell Modeling on DCM
Fayssoil, A., Orlikowski, D., Nardi, O., and Annane, D. (2010). Pacemaker
implantation for sinus node dysfunction in a young patient with duchenne
muscular dystrophy. Congest. Heart Fail. 16, 127–128.
Fayssoil, A., Ritzenthaler, T., Luis, D., Hullin, T., Clair, B., Annane, D., et al.
(2014). Be careful about abdominal discomfort in adult patients with muscular
dystrophy. Res. Neurol. 170, 548–550. doi: 10.1016/j.neurol.2014.06.003
Ferrantini, C., Pioner, J. M., Martella, D., Coppini, R., Piroddi, N., Paoli, P., et al.
(2019). Development of light-responsive liquid crystalline elastomers to assist
cardiac contraction. Circ. Res. 124, e44–e54. doi: 10.1161/CIRCRESAHA.118.
313889
Ferrantini, C., Pioner, J. M., Mazzoni, L., Gentile, F., Tosi, B., Rossi, A., et al.
(2018). Late sodium current inhibitors to treat exercise-induced obstruction in
hypertrophic cardiomyopathy: an in vitro study in human myocardium. Br. J.
Pharmacol. 175, 2635–2652. doi: 10.1111/bph.14223
Frank, D., Yusuf Rangrez, A., Friedrich, C., Dittmann, S., Stallmeyer, B., Yadav, P.,
et al. (2019). Cardiac alpha-Actin (ACTC1) gene mutation causes atrial-septal
defects associated with late-onset dilated cardiomyopathy. Circ. Genomic Preci.
Med. 12, e002491. doi: 10.1161/CIRCGEN.119.002491
Frankel, K. A., and Rosser, R. J. (1976). The pathology of the heart in progressive
muscular dystrophy: epimyocardial fibrosis. Hum. Pathol. 7, 375–386.
Gartz, M., Darlington, A., Afzal, M. Z., and Strande, J. L. (2018). Exosomes
exert cardioprotection in dystrophin-deficient cardiomyocytes via ERK1/2-
p38/MAPK signaling. Sci. Rep. 8, 16519. doi: 10.1038/s41598-018-34879-6
Gherghiceanu, M., Barad, L., Novak, A., Reiter, I., Itskovitz-Eldor, J., Binah, O.,
et al. (2011). Cardiomyocytes derived from human embryonic and induced
pluripotent stem cells: comparative ultrastructure. J. Cell. Mol. Med. 15, 2539–
2551. doi: 10.1111/j.1582-4934.2011.01417.x
Giatrakos, N., Kinali, M., Stephens, D., Dawson, D., Muntoni, F., and
Nihoyannopoulos, P. (2006). Cardiac tissue velocities and strain rate in the early
detection of myocardial dysfunction of asymptomatic boys with duchenne’s
muscular dystrophy: relationship to clinical outcome. Heart 92, 840–842.
Gigli, M., Merlo, M., Graw, S. L., Barbati, G., Rowland, T. J., Slavov, D. B.,
et al. (2019). Genetic risk of arrhythmic phenotypes in patients with dilated
cardiomyopathy. J. Am. Coll. Cardiol. 74, 1480–1490. doi: 10.1016/j.jacc.2019.
06.072
Gowran, A., Spaltro, G., Casalnuovo, F., Vigorelli, V., Spinelli, P., and Castiglioni,
E. (2018). Generation of induced pluripotent stem cells from a Becker muscular
dystrophy patient carrying a deletion of exons 45-55 of the dystrophin gene
(CCMi002BMD-A-9 45-55). Stem Cell Res. 28, 21–24. doi: 10.1016/j.scr.2018.
01.025
Guan, X., Mack, D. L., Moreno, C. M., Strande, J. L., Mathieu, J., and Shi, Y. (2014).
Dystrophin-deficient cardiomyocytes derived from human urine: new biologic
reagents for drug discovery. Stem Cell Res. 12, 467–480. doi: 10.1016/j.scr.2013.
12.004
Gupta, N., Susa, K., Yoda, Y., Bonventre, J. V., Valerius, M. T., and Morizane, R.
(2018). CRISPR/Cas9-based targeted genome editing for the development of
monogenic diseases models with human pluripotent stem cells. Curr. Protoc.
Stem Cell Biol. 45:e50. doi: 10.1002/cpsc.50
Hasselberg, N. E., Haland, T. F., Saberniak, J., Brekke, P. H., Berge, K. E., Leren,
T. P., et al. (2018). Lamin A/C cardiomyopathy: young onset, high penetrance,
and frequent need for heart transplantation. Eur. Heart J. 39, 853–860. doi:
10.1093/eurheartj/ehx596
Hershberger, R. E., Hedges, D. J., and Morales, A., (2013). Dilated cardiomyopathy:
the complexity of a diverse genetic architecture. Na. Rev. Cardiol. 10, 531–547.
doi: 10.1038/nrcardio.2013.105
Hinson, J. T., Chopra, A., Nafissi, N., Polacheck, W. J., Benson, C. C., Swist, S.,
et al. (2015). HEART DISEASE. Titin mutations in iPS cells define sarcomere
insufficiency as a cause of dilated cardiomyopathy. Science 349, 982–986. doi:
10.1126/science.aaa5458
Hof, I. E., van der Heijden, J. F., Kranias, E. G., Sanoudou, D., de Boer,
R. A., van Tintelen, J. P., et al. (2019). Prevalence and cardiac phenotype
of patients with a phospholamban mutation. Netherlands Heart J. 27,
64–69.
Hoffman, E. P., Brown, R. H. Jr., and Kunkel, L. M. (1987). Dystrophin: the protein
product of the Duchenne muscular dystrophy locus. Cell 51, 919–928.
Huebsch, N., Loskill, P., Mandegar, M. A., Marks, N. C., Sheehan, A. S., Ma, Z.,
et al. (2015). Automated video-based analysis of contractility and calcium flux
in human-induced pluripotent stem cell-derived cardiomyocytes cultured over
different spatial scales. Tissue Eng Part C 21, 467–479. doi: 10.1089/ten.TEC.
2014.0283
Iodice, F., Testa, G., Averardi, M., Brancaccio, G., Amodeo, A., and Cogo, P.
(2015). Implantation of a left ventricular assist device as a destination therapy
in Duchenne muscular dystrophy patients with end stage cardiac failure:
management and lessons learned. Neuromusc. Disord.25, 19–23. doi: 10.1016/j.
nmd.2014.08.008
Iorga, B., Schwanke, K., Weber, N., Wendland, M., Greten, S., Piep, B., et al. (2017).
Differences in contractile function of myofibrils within human embryonic
stem cell-derived cardiomyocytes vs. adult ventricular myofibrils are related to
distinct sarcomeric protein isoforms. Front. Physiol. 8:1111. doi: 10.3389/fphys.
2017.01111
Itzhaki, I., Schiller, J., Beyar, R., Satin, J., and Gepstein, L., (2006). Calcium handling
in embryonic stem cell-derived cardiac myocytes: of mice and men. Ann. N. Y.
Acad. Sci. 1080, 207–215.
Japp, A. G., Gulati, A., Cook, S. A., Cowie, M. R., and Prasad, S. K., (2016). The
diagnosis and evaluation of dilated cardiomyopathy. J. Am. Coll. Cardiol. 67,
2996–3010. doi: 10.1016/j.jacc.2016.03.590
Jelinkova, S., Fojtik, P., Kohutova, A., Vilotic, A., Markova, L., Pesl, M., et al.
(2019). Dystrophin deficiency leads to genomic instability in human pluripotent
stem cells via no synthase-induced oxidative stress. Cells 8:53. doi: 10.3390/
cells8010053
Judge, L. M., Perez-Bermejo, J. A., Truong, A., Ribeiro, A. J., Yoo, J. C., and Jensen,
C. L. (2017). A BAG3 chaperone complex maintains cardiomyocyte function
during proteotoxic stress. JCI Insight 2:e94623. doi: 10.1172/jci.insight.94623
Kaestner, L., Scholz, A., Tian, Q. H., Ruppenthal, S., Tabellion, W., and Wiesen,
K. (2014). Genetically Encoded Ca2+ indicators in cardiac myocytes. Circ. Res.
114, 1623–1639. doi: 10.1161/CIRCRESAHA.114.303475
Kaprielian, R. R., and Severs, N. J. (2000). Dystrophin and the cardiomyocyte
membrane cytoskeleton in the healthy and failing heart. Heart Fail Rev. 5,
221–238.
Kaprielian, R. R., Stevenson, S., Rothery, S. M., Cullen, M. J., and Severs, N. J.
(2000). Distinct patterns of dystrophin organization in myocyte sarcolemma
and transverse tubules of normal and diseased human myocardium. Circulation
101, 2586–2594.
Karakikes, I., Stillitano, F., Nonnenmacher, M., Tzimas, C., Sanoudou, D.,
and Termglinchan, V. (2015). Correction of human phospholamban R14del
mutation associated with cardiomyopathy using targeted nucleases and
combination therapy. Nat. Commun. 6:6955. doi: 10.1038/ncomms7955
Klimas, A., Ambrosi, C. M., Yu, J. Z., Williams, J. C., Bien, H., and Entcheva,
E. (2016). OptoDyCE as an automated system for high-throughput all-optical
dynamic cardiac electrophysiology. Nat. Commun. 7:11542. doi: 10.1038/
ncomms11542
Koopmann, T. T., Verkerk, A. O., Bezzina, C. R., de Bakker, J. M., and Wilde,
A. A. (2012). The chemical compound PTC124 does not affect cellular
electrophysiology of cardiac ventricular myocytes. Cardiovascu. Drugs Ther. 26,
41–45.
Kyrychenko, V., Kyrychenko, S., Tiburcy, M., Shelton, J. M., Long, C., and
Schneider, J. W. (2017). Functional correction of dystrophin actin binding
domain mutations by genome editing. JCI Insight 2:e95918. doi: 10.1172/jci.
insight.95918
Le, S., Yu, M., Hovan, L., Zhao, Z., Ervasti, J., and Yan, J. (2018). Dystrophin As a
Molecular Shock Absorber. ACS Nano 12, 12140–12148. doi: 10.1021/acsnano.
8b05721
Lee, Y. K., Lau, Y. M., Cai, Z. J., Lai, W. H., Wong, L. Y., Tse, H. F., et al. (2017).
Modeling treatment response for lamin A/C related dilated cardiomyopathy
in human induced pluripotent stem cells. J. Am. Heart Assoc. 6:e005677. doi:
10.1161/JAHA.117.005677
Leyva-Leyva, M., Sandoval, A., Felix, R., and Gonzalez-Ramirez, R. (2018).
Biochemical and functional interplay between ion channels and the
components of the dystrophin-associated glycoprotein complex. J. Memb. Biol.
251, 535–550. doi: 10.1007/s00232-018-0036-9
Li, X., Lu, W. J., Li, Y., Wu, F., Bai, R., Ma, S., et al. (2019). MLP-deficient
human pluripotent stem cell derived cardiomyocytes develop hypertrophic
cardiomyopathy and heart failure phenotypes due to abnormal calcium
handling. Cell Death Dis. 10:610. doi: 10.1038/s41419-019-1826-4
Liang, W., Duan, Y. P., Shang, B. R., Wang, Y. P., Hu, C., and Lippke, S. (2019).
A web-based lifestyle intervention program for Chinese college students: study
Frontiers in Physiology | www.frontiersin.org 19 May 2020 | Volume 11 | Article 368
fphys-11-00368 May 10, 2020 Time: 19:26 # 20
Pioner et al. Impact of DMD-Stem Cell Modeling on DCM
protocol and baseline characteristics of a randomized placebo-controlled trial.
BMC Public Health 19:1097. doi: 10.1186/s12889-019-7438-1
Lin, B., Li, Y., Han, L., Kaplan, A. D., Ao, Y., Kalra, S., et al. (2015). Modeling and
study of the mechanism of dilated cardiomyopathy using induced pluripotent
stem cells derived from individuals with duchenne muscular dystrophy. Dis.
Models Mech. 8, 457–466. doi: 10.1242/dmm.019505
Lipshultz, S. E., Sleeper, L. A., Towbin, J. A., Lowe, A. M., Orav, E. J., Cox, G. F.,
et al. et al. (2003). The incidence of pediatric cardiomyopathy in two regions of
the United States. N. Eng. J. Med. 348, 1647–1655.
Long, C., Li, H., Tiburcy, M., Rodriguez-Caycedo, C., Kyrychenko, V., and Zhou,
H. (2018). Correction of diverse muscular dystrophy mutations in human
engineered heart muscle by single-site genome editing. Sci. Adv. 4:eaa9004.
doi: 10.1126/sciadv.aap9004
Lundy, S. D., Zhu, W. Z., Regnier, M., and Laflamme, M. A., (2013). Structural and
functional maturation of cardiomyocytes derived from human pluripotent stem
cells. Stem Cells Dev. 22, 1991–2002. doi: 10.1089/scd.2012.0490
Macadangdang, J., Guan, X., Smith, A. S., Lucero, R., Czerniecki, S., Childers, M. K.,
et al. (2015). Nanopatterned Human iPSC-based model of a dystrophin-null
cardiomyopathic phenotype. Cell. Mol. Bioeng. 8, 320–332.
Macadangdang, J., Lee, H. J., Carson, D., Jiao, A., Fugate, J., Pabon, L., et al.
(2014). Capillary force lithography for cardiac tissue engineering. J. Visual. Exp.
88:e50039. doi: 10.3791/50039
Madhavan, R., and Jarrett, H. W. (1994). Calmodulin-activated phosphorylation of
dystrophin. Biochemistry 33:5797–5804.
Mandel, J. L. (1989). Dystrophin. The gene and its product. Nature 339, 584–586.
Manning, G. W., and Cropp, G. J. (1958). The electrocardiogram in progressive
muscular dystrophy. Br. Heart J. 20, 416–420.
Markham, L. W., Kinnett, K., Wong, B. L., Woodrow Benson, D., and Cripe,
L. H. (2008). Corticosteroid treatment retards development of ventricular
dysfunction in Duchenne muscular dystrophy. Neuromusc. Disord. 18,
365–370.
Markham, L. W., Michelfelder, E. C., Border, W. L., Khoury, P. R., Spicer, R. L.,
and Wong, B. L. (2006). Abnormalities of diastolic function precede dilated
cardiomyopathy associated with Duchenne muscular dystrophy. J. Am. Soc.
Echocardiogr. 19, 865–871.
Maroto, R., Raso, A., Wood, T. G., Kurosky, A., Martinac, B., and Hamill, O. P.
(2005). TRPC1 forms the stretch-activated cation channel in vertebrate cells.
Nat. Cell Biol. 7, 179–185.
Martella, D., Paoli, P., Pioner, J. M., Sacconi, L., Coppini, R., Santini, L., et al.
(2017). Liquid crystalline networks toward regenerative medicine and tissue
repair. Small 13:46. doi: 10.1002/smll.201702677
Massourides, E., Polentes, J., Mangeot, P. E., Mournetas, V., Nectoux, J.,
Deburgrave, N., et al. (2015). Dp412e: a novel human embryonic dystrophin
isoform induced by BMP4 in early differentiated cells. Skeletal Muscle 5:40.
doi: 10.1186/s13395-015-0062-6
McNair, W. P., Sinagra, G., Taylor, M. R., Di Lenarda, A., Ferguson, D. A., et al.
(2011). SCN5A mutations associate with arrhythmic dilated cardiomyopathy
and commonly localize to the voltage-sensing mechanism. J. Am. Coll. Cardiol.
57, 2160–2168. doi: 10.1016/j.jacc.2010.09.084
McNally, E. M. (2007). New approaches in the therapy of cardiomyopathy in
muscular dystrophy. Ann. Rev. Med. 58, 75–88.
McNally, E. M. (2017). Cardiomyopathy in muscular dystrophy: when to treat?
JAMA Cardiol. 2:199.
McNally, E. M., Kaltman, J. R., Benson, D. W., Canter, C. E., Cripe, L. H., Duan, D.,
et al. (2015). Parent project muscular, contemporary cardiac issues in duchenne
muscular dystrophy. working group of the national heart, lung, and blood
institute in collaboration with parent project muscular dystrophy. Circulation
131, 1590–1598.
McNally, E. M., and Mestroni, L., (2017). Dilated cardiomyopathy: genetic
determinants and mechanisms. Circ. Res. 121, 731–748.
Mendell, J. R., Shilling, C., Leslie, N. D., Flanigan, K. M., R. al-Dahhak, J.
Gastier-Foster, et al. (2012). Evidence-based path to newborn screening for
duchenne muscular dystrophy. Ann. Neurol. 71 304–313. doi: 10.1002/ana.
23528
Meng, H., Leddy, J. J., Frank, J., Holland, P., and Tuana, B. S. (1996). The
association of cardiac dystrophin with myofibrils/Z-disc regions in cardiac
muscle suggests a novel role in the contractile apparatus. T J. Bio. Chem. 271,
12364–12371.
Merlo, M., Sinagra, G., Carniel, E., Slavov, D., Zhu, X., Barbati, G., et al. (2013).
Poor prognosis of rare sarcomeric gene variants in patients with dilated
cardiomyopathy. Clin. Trans. Sci. 6, 424–428. doi: 10.1111/cts.12116
Merrick, D., Stadler, L. K., Larner, D., and Smith, J. (2009). Muscular dystrophy
begins early in embryonic development deriving from stem cell loss and
disrupted skeletal muscle formation. Dis. Models Mech. 2, 374–388. doi: 10.
1242/dmm.001008
Mertens, L., Ganame, J., Claus, P., Goemans, N., Thijs, D., and Eyskens, B.
(2008). Early regional myocardial dysfunction in young patients with duchenne
muscular dystrophy. J. Am. Soc. Echocardiogr. 21, 1049–1054.
Mestroni, L., Brun, F., Spezzacatene, A., Sinagra, G., and Taylor, M. R. (2014).
Genetic causes of dilated cardiomyopathy. Prog. Pediatr. Cardiol. 37, 13–18.
Min, Y. L., Li, H., Rodriguez-Caycedo, C., Mireault, A. A., Huang, J., and Shelton,
J. M. (2019). CRISPR-Cas9 corrects duchenne muscular dystrophy exon 44
deletion mutations in mice and human cells. Sci. Adv. 5:eaav4324. doi: 10.1126/
sciadv.aav4324
Mitzelfelt, K. A., Limphong, P., Choi, M. J., Kondrat, F. D., Lai, S., and Kolander,
K. D. (2016). The Human 343delT HSPB5 chaperone associated with early-
onset skeletal myopathy causes defects in protein solubility. J. Biol Chem. 291,
14939–14953. doi: 10.1074/jbc.M116.730481
Mora, M., Di Blasi, C., Barresi, R., Morandi, L., Brambati, B., Jarre, L., et al. (1996).
Developmental expression of dystrophin, dystrophin-associated glycoproteins
and other membrane cytoskeletal proteins in human skeletal and heart muscle.
Brain Res.. Dev. Brain Res. 91, 70–82.
Mora, M., Morandi, L., Merlini, L., Vita, G., Baradello, A., and Barresi, R. (1994).
Fetus-like dystrophin expression and other cytoskeletal protein abnormalities
in centronuclear myopathies. Muscle Nerve 17, 1176–1184.
Moreau, A., Gosselin-Badaroudine, P., Mercier, A., Burger, B., Keller, D. I., and
Chahine, M. (2018). A leaky voltage sensor domain of cardiac sodium channels
causes arrhythmias associated with dilated cardiomyopathy. Sci. Rep. 8:13804.
doi: 10.1038/s41598-018-31772-0
Moretti, A., Fonteyne, L., Giesert, F., Hoppmann, P., Meier, A. B., Bozoglu, T., et al.
(2020). Somatic gene editing ameliorates skeletal and cardiac muscle failure
in pig and human models of duchenne muscular dystrophy. Nat. Med. 26,
207–214. doi: 10.1038/s41591-019-0738-2
Mosqueira, M., Zeiger, U., Forderer, M., Brinkmeier, H., and Fink, R. H. (2013).
Cardiac and respiratory dysfunction in duchenne muscular dystrophy and the
role of second messengers. Med. Res. Rev. 33, 1174–1213. doi: 10.1002/med.
21279
Muntoni, F. (2003). Cardiomyopathy in muscular dystrophies. Curr,. Opin. Neurol.
16, 577–583.
Muntoni, F., Torelli, S., and Ferlini, A. (2003). Dystrophin and mutations: one gene,
several proteins, multiple phenotypes. Lancet. Neurol. 2, 731–740.
Nanni, S., Re, A., Ripoli, C., Gowran, A., Nigro, P., D’Amario, D., et al. (2016). The
nuclear pore protein Nup153 associates with chromatin and regulates cardiac
gene expression in dystrophic mdx hearts. Cardiovasc. Res. 112, 555–567. doi:
10.1093/cvr/cvw204
Ng, R., Manring, H., Papoutsidakis, N., Albertelli, T., Tsai, N., and See, C. J. (2019).
Patient mutations linked to arrhythmogenic cardiomyopathy enhance calpain-
mediated desmoplakin degradation. JCI Insight 5:e128643. doi: 10.1172/jci.
insight.128643
Nigro, G., Comi, L. I., Politano, L., and Bain, R. J. (1990). The incidence and
evolution of cardiomyopathy in duchenne muscular dystrophy. Int. J. Cardiol.
26, 271–277.
Nunes, S. S., Miklas, J. W., Liu, J., R. Aschar-Sobbi, Xiao, Y., Zhang, B., et al. (2013).
Biowire: a platform for maturation of human pluripotent stem cell-derived
cardiomyocytes. Nat. Methods 10, 781–787. doi: 10.1038/nmeth.2524
Ortiz-Genga, MF, Cuenca, S, Dal Ferro, M, Zorio, E, Salgado-Aranda, R, Climent,
V, (2016). Truncating FLNC mutations are associated with high-risk dilated and
arrhythmogenic cardiomyopathies. J. Am. Coll. Cardiol. 68, 2440–2451.
Perloff, J. K. (1984). Cardiac rhythm and conduction in duchenne’s muscular
dystrophy: a prospective study of 20 patients. J. Am. Coll. Cardiol. 3, 1263–1268.
Pioner, J. M., Guan, X., Klaiman, J. M., Racca, A. W., Pabon, L., and Muskheli,
V. (2019a). Absence of full-length dystrophin impairs normal maturation and
contraction of cardiomyocytes derived from human induced pluripotent stem
cells. Cardiovas. Res. 116, 368–382. doi: 10.1093/cvr/cvz109
Pioner, J. M., Santini, L., Palandri, C., Martella, D., Lupi, F., Langione, M.,
et al. (2019b). Optical investigation of action potential and calcium handling
Frontiers in Physiology | www.frontiersin.org 20 May 2020 | Volume 11 | Article 368
fphys-11-00368 May 10, 2020 Time: 19:26 # 21
Pioner et al. Impact of DMD-Stem Cell Modeling on DCM
maturation of hiPSC-Cardiomyocytes on biomimetic substrates. Int. J. Mol. Sci.
20:3799. doi: 10.3390/ijms20153799
Pioner, J. M., Racca, A. W., Klaiman, J. M., Yang, K. C., Guan, X., Pabon,
L., et al. (2016). Isolation and mechanical measurements of myofibrils from
human induced pluripotent stem cell-derived cardiomyocytes. Stem Cell Rep.
6, 885–896. doi: 10.1016/j.stemcr.2016.04.006
Priori, S. G., Blomstrom-Lundqvist, C., Mazzanti, A., Blom, N., Borggrefe, M.,
Camm, J., et al. (2015). 2015 ESC guidelines for the management of patients
with ventricular arrhythmias and the prevention of sudden cardiac death: the
task force for the management of patients with ventricular arrhythmias and
the prevention of sudden cardiac death of the European Society of Cardiology
(ESC). Endorsed by: association for European Paediatric and Congenital
Cardiology (AEPC). Eur. Heart J. 36, 2793–2867.
Racca, A. W., Klaiman, J. M., Pioner, J. M., Cheng, Y., Beck, A. E., Moussavi-
Harami, F., et al. (2016). Contractile properties of developing human fetal
cardiac muscle. J. Physiol 594, 437–452. doi: 10.1113/JP271290
Rahimov, F., and Kunkel, L. M. (2013). The cell biology of disease: cellular
and molecular mechanisms underlying muscular dystrophy. J. Cell Biol. 201,
499–510. doi: 10.1083/jcb.201212142
Rakar, S., Sinagra, G., Di Lenarda, A., Poletti, A., Bussani, R., Silvestri, F., et al.
(1997). Epidemiology of dilated cardiomyopathy. a prospective post-mortem
study of 5252 necropsies. the heart muscle disease study group. Eur. Heart J. 18,
117–123.
Refaat, M. M., Lubitz, S. A., Makino, S., Islam, Z., Frangiskakis, J. M., Mehdi, H.,
et al. (2012). Genetic variation in the alternative splicing regulator RBM20 is
associated with dilated cardiomyopathy. Heart Rhythm 9, 390–396. doi: 10.
1016/j.hrthm.2011.10.016
Reiser, P. J., Portman, M. A., Ning, X. H., and C. Schomisch Moravec, (2001).
Human cardiac myosin heavy chain isoforms in fetal and failing adult atria and
ventricles. American journal of physiology. Heart Circ. Physiol. 280, H1814–
H1820.
Ribeiro, M. C., Tertoolen, L. G., Guadix, J. A., Bellin, M., Kosmidis, G., C.
D’Aniello, J et al. (2015).Functional maturation of human pluripotent stem
cell derived cardiomyocytes in vitro–correlation between contraction force and
electrophysiology. Biomaterials 51, 138–150. doi: 10.1016/j.biomaterials.2015.
01.067
Ripoll-Vera, T., Gámez, J. M., Govea, N., Gómez, Y., Núñez, J., Socías, L.,
et al. (2016). Clinical and prognostic profiles of cardiomyopathies caused by
mutations in the troponin T Gene. Rev. Espanola Cardiol. 69, 149–158. doi:
10.1016/j.rec.2015.06.025
Rohani, L., Machiraju, P., Sabouny, R., Meng, G., Liu, S., Zhao, T., et al. (2020).
Reversible mitochondrial fragmentation in iPSC-derived cardiomyocytes from
children with DCMA, a mitochondrial cardiomyopathy. Can. J. Cardiol. 36,
554–563. doi: 10.1016/j.cjca.2019.09.021
Ronaldson-Bouchard, K., Ma, S. P., Yeager, K., Chen, T., Song, L., Sirabella, D., et al.
(2018). Advanced maturation of human cardiac tissue grown from pluripotent
stem cells. Nature 556, 239–243. doi: 10.1038/s41586-018-0016-3
Ronaldson-Bouchard, K., Yeager, K., Teles, D., Chen, T., Ma, S., Song, L., et al.
(2019). Engineering of human cardiac muscle electromechanically matured to
an adult-like phenotype. Nat. Protoc. 14, 2781–2817. doi: 10.1038/s41596-019-
0189-8
Salvarani, N., Crasto, S., Miragoli, M., Bertero, A., Paulis, M., Kunderfranco, P.,
et al. (2019). The K219T-Lamin mutation induces conduction defects through
epigenetic inhibition of SCN5A in human cardiac laminopathy. Nat. Commun.
10:2267. doi: 10.1038/s41467-019-09929-w
Sartiani, L., Bettiol, E., Stillitano, F., Mugelli, A., Cerbai, E., Jaconi, M. E., et al.
(2007). Developmental changes in cardiomyocytes differentiated from human
embryonic stem cells: a molecular and electrophysiological approach. StemCells
25, 1136–1144.
Sasse, S., Brand, N. J., Kyprianou, P., Dhoot, G. K., Wade, R., Arai, M., et al.
(1993). Troponin I gene expression during human cardiac development and
in end-stage heart failure. Circ. Res. 72, 932–938.
Sato, M., Shiba, N., Miyazaki, D., Shiba, Y., Echigoya, Y., and Yokota, T.
(2019). Amelioration of intracellular Ca(2+) regulation by exon-45 skipping
in Duchenne muscular dystrophy-induced pluripotent stem cell-derived
cardiomyocytes. Biochem Biophys. Res. Commun. 520, 179–185. doi: 10.1016/
j.bbrc.2019.09.095
Schick, R., Mekies, L. N., Shemer, Y., Eisen, B., Hallas, T., Ben Jehuda
R., et al. (2018). Functional abnormalities in induced pluripotent Stem
Cell-derived cardiomyocytes generated from titin-mutated patients With
dilated cardiomyopathy. PloS One 13:e0205719.
Schmitt, J. P., Kamisago, M., Asahi, M., Li, G. H., Ahmad, F., Mende, U., et al.
(2003). Dilated cardiomyopathy and heart failure caused by a mutation in
phospholamban. Science 299, 1410–1413.
Shafaattalab, S., Li, A. Y., Lin, E., Stevens, C. M., Dewar, L. J., and Lynn, F. C. (2019).
In vitro analyses of suspected arrhythmogenic thin filament variants as a cause
of sudden cardiac death in infants. Proc. Natl. Acad. Sci. U.S.A. 116, 6969–6974.
doi: 10.1073/pnas.1819023116
Shah, D., Virtanen, L., Prajapati, C., Kiamehr, M., Gullmets, J., West, G., et al.
(2019). Modeling of LMNA-related dilated cardiomyopathy using human
induced pluripotent stem cells. Cells 8:594.
Shaheen, N., Shiti, A., Huber, I., Shinnawi, R., Arbel, G., and Gepstein, A.
(2018). Human induced pluripotent stem cell-derived cardiac cell sheets
expressing genetically encoded voltage indicator for pharmacological and
arrhythmia studies. Stem cell Rep. 10, 1879–1894. doi: 10.1016/j.stemcr.2018.
04.006
Shimojima, M., Yuasa, S., Motoda, C., Yozu, G., Nagai, T., Ito, S., et al. (2017).
Emerin plays a crucial role in nuclear invagination and in the nuclear calcium
transient. Sci. Rep. 7, 44312. doi: 10.1038/srep44312
Shirokova, N., and Niggli, E. (2013). Cardiac phenotype of duchenne muscular
dystrophy: insights from cellular studies. J. Mol. Cell. Cardiol. 58, 217–224.
doi: 10.1016/j.yjmcc.2012.12.009
Silva, M. C., Magalhaes, T. A., Meira, Z. M., Rassi, C. H., Andrade, A. C., Gutierrez,
P. S., et al. (2017). Myocardial fibrosis progression in duchenne and becker
muscular dystrophy: a randomized clinical trial. JAMA Cardiol. 2, 190–199.
Siu, C. W., Lee, Y. K., Ho, J. C., Lai, W. H., Chan, Y. C., Ng, K. M., et al. (2012).
Modeling of lamin A/C mutation premature cardiac aging using patient-specific
induced pluripotent stem cells. Aging 4, 803–822.
Stillitano, F., Turnbull, I. C., Karakikes, I., Nonnenmacher, M., Backeris, P., and
Hulot, J. S. (2016). Genomic correction of familial cardiomyopathy in human
engineered cardiac tissues. Eur. Heart J. 37, 3282–3284.
Streckfuss-Bomeke, K, Tiburcy, M., Fomin, A., Luo, X., Li, W., Fischer, C.,
et al. (2017). Severe DCM phenotype of patient harboring RBM20 mutation
S635A can be modeled by patient-specific induced pluripotent stem cell-derived
cardiomyocytes. J. Mol. Cell Cardiol. 113, 9–21. doi: 10.1016/j.yjmcc.2017.
09.008
Stroik, D. R., Ceholski, D. K., Bidwell, P. A., Mleczko, J., Thanel, P. F., and Kamdar,
F. (2019). Viral expression of a SERCA2a-activating PLB mutant improves
calcium cycling and synchronicity in dilated cardiomyopathic hiPSC-CMs.
J. Mol. Cell. Cardiol. 138, 59–65. doi: 10.1016/j.yjmcc.2019.11.147
Sun, N., Yazawa, M., Liu, J., Han, L., Sanchez-Freire, V., and Abilez, O. J.
(2012). Patient-specific induced pluripotent stem cells as a model for familial
dilated cardiomyopathy. Sci. Transl. Med. 4, 130ra47. doi: 10.1126/scitranslmed.
3003552
Sun, X., and Nunes, S. S. (2017). Bioengineering approaches to mature human
pluripotent stem Cell-Derived cardiomyocytes. Front. Cell Dev. Biol. 5:19. doi:
10.3389/fcell.2017.00019
Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from
mouse embryonic and adult fibroblast cultures by defined factors. Cell 126,
663–676.
Takami, Y., Takeshima, Y., Awano, H., Okizuka, Y., Yagi, M., and Matsuo, M.
(2008). High incidence of electrocardiogram abnormalities in young patients
with duchenne muscular dystrophy. Pediatr. Neurol 39, 399–403. doi: 10.1016/
j.pediatrneurol.2008.08.006
Takasaki, A., Hirono, K., Hata, Y., Wang, C., Takeda, M., Yamashita, J. K.,
et al. (2018). Sarcomere gene variants act as a genetic trigger underlying the
development of left ventricular noncompaction. Pediatr. Res. 84, 733–742. doi:
10.1038/s41390-018-0162-1
Tardiff, J. C., Carrier, L., Bers, D. M., Poggesi, C., Ferrantini, C., and Coppini, R.
(2015). Targets for therapy in sarcomeric cardiomyopathies. Cardiovasc Res.
105, 457–470. doi: 10.1093/cvr/cvv023
Taylor, M. R., Slavov, D., Ku, L., Lenarda, A. Di, Sinagra, G., Carniel, E., et al. (2007).
Prevalence of desmin mutations in dilated cardiomyopathy. Circulation 115,
1244–1251.
Towbin, J. A., Hejtmancik, J. F., Brink, P., Gelb, B., Zhu, X. M., Chamberlain, J. S.,
et al. (1993). X-linked dilated cardiomyopathy. Molecular genetic evidence of
linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21
locus. Circulation 87, 1854–1865.
Frontiers in Physiology | www.frontiersin.org 21 May 2020 | Volume 11 | Article 368
fphys-11-00368 May 10, 2020 Time: 19:26 # 22
Pioner et al. Impact of DMD-Stem Cell Modeling on DCM
Traister, A., Li, M., Aafaqi, S., Lu, M., Arab, S., Radisic, M., et al. (2014). Integrin-
linked kinase mediates force transduction in cardiomyocytes by modulating
SERCA2a/PLN function. Nat. Commun. 5, 4533. doi: 10.1038/ncomms5533
Tse, H. F., Ho, J. C., Choi, S. W., Lee, Y. K., Butler, A. W., Ng, K. M., et al.
(2013). Patient-specific induced-pluripotent stem cells-derived cardiomyocytes
recapitulate the pathogenic phenotypes of dilated cardiomyopathy due to a
novel DES mutation identified by whole exome sequencing. Hum. Mol. Genet.
22, 1395–1403. doi: 10.1093/hmg/dds556
Tsurumi, F., Baba, S., Yoshinaga, D., Umeda, K., Hirata, T., Takita, J., et al.
(2019). The intracellular Ca2+ concentration is elevated in cardiomyocytes
differentiated from hiPSCs derived from a Duchenne muscular dystrophy
patient. PloS One 14:e0213768. doi: 10.1371/journal.pone.0213768
Tulloch, N. L., Muskheli, V., Razumova, M. V., Korte, F. S., Regnier, M.,
Hauch, K. D., et al. (2011). Growth of engineered human myocardium with
mechanical loading and vascular coculture. Circ. Res. 109, 47–59. doi: 10.1161/
CIRCRESAHA.110.237206
Ulmer, B. M., and Eschenhagen, T., (2019). Human pluripotent stem cell-derived
cardiomyocytes for studying energy metabolism. Biochim. Biophys. Acta. Mol.
Cell Res. 1867: 118471 doi: 10.1016/j.bbamcr.2019.04.001
van den Berg, C. W., Okawa, S., Chuva de Sousa Lopes , S. M., van Iperen, L.,
Passier, R., Braam, S. R., et al. (2015). Transcriptome of human foetal heart
compared with cardiomyocytes from pluripotent stem cells. Development 142,
3231–3238. doi: 10.1242/dev.123810
van der Zwaag, P. A., van Rijsingen , I. A., Asimaki, A., Jongbloed, J. D.,
van Veldhuisen , D. J., Wiesfeld, A. C., et al. (2012). Phospholamban
R14del mutation in patients diagnosed with dilated cardiomyopathy or
arrhythmogenic right ventricular cardiomyopathy: evidence supporting the
concept of arrhythmogenic cardiomyopathy. Eur. J. Heart Fail. 14, 1199–1207.
doi: 10.1093/eurjhf/hfs119
Vasile, V. C., Will, M. L., Ommen, S. R., Edwards, W. D., Olson, T. M., and
Ackerman, M. J. (2006). Identification of a metavinculin missense mutation,
R975W, associated with both hypertrophic and dilated cardiomyopathy. Mol.
Genet. Metab. 87, 169–174.
Verdonschot JAJ, Hazebroek MR, Derks KWJ, Barandiarán Aizpurua A, Merken
JJ, Wang P, et al. (2018). Titin cardiomyopathy leads to altered mitochondrial
energetics, increased fibrosis and long-term life-threatening arrhythmias. Eur.
Heart J. 39, 864–873. doi: 10.1093/eurheartj/ehx808
Vogel, C., and Marcotte, E. M. (2012). Insights into the regulation of protein
abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet. 13,
227–232. doi: 10.1038/nrg3185
Wang, G., McCain, M. L., Yang, L., He, A., Pasqualini, F. S., and Agarwal, A. (2014).
Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced
pluripotent stem cell and heart-on-chip technologies. Nat. Med. 20, 616–623.
doi: 10.1038/nm.3545
Wang, L., Kim, K., Parikh, S., Cadar, A. G., Bersell, K. R., He, H., et al.
(2018). Hypertrophic cardiomyopathy-linked mutation in troponin T causes
myofibrillar disarray and pro-arrhythmic action potential changes in human
iPSC cardiomyocytes. J. Mol. Cell. Cardiol. 114, 320–327. doi: 10.1016/j.yjmcc.
2017.12.002
Wang, M., Birnkrant, D. J., Super, D. M., Jacobs, I. B., and Bahler, R. C. (2018).
Progressive left ventricular dysfunction and long-term outcomes in patients
with Duchenne muscular dystrophy receiving cardiopulmonary therapies.
Open Heart 5:e000783. doi: 10.1136/openhrt-2018-000783
Weber, N., Schwanke, K., Greten, S., Wendland, M., Iorga, B., Fischer, M.,
et al. (2016). Stiff matrix induces switch to pure beta-cardiac myosin heavy
chain expression in human ESC-derived cardiomyocytes. Basic Res. Cardiol.
111:68.
Welch, E. M., Barton, E. R., Zhuo, J., Tomizawa, Y., Friesen, W. J., and Trifillis,
P. (2007). targets genetic disorders caused by nonsense mutations. Nature 447,
87–91.
Wolska, B. M., Vijayan, K., Arteaga, G. M., Konhilas, J. P., Phillips, R. M., Kim, R.,
et al. (2001). Expression of slow skeletal troponin I in adult transgenic mouse
heart muscle reduces the force decline observed during acidic conditions.
J. Physiol. 536, 863–870.
Wu, H., Lee, J., Vincent, L. G., Wang, Q., Gu, M., and Lan, F. (2015). Epigenetic
regulation of phosphodiesterases 2A and 3A underlies compromised beta-
adrenergic signaling in an iPSC Model of dilated cardiomyopathy. Cell Stem
Cell 17, 89–100.
Wyles, S. P., Hrstka, S. C., Reyes, S., Terzic, A., Olson, T. M., and Nelson, T. J.
(2016a). Pharmacological modulation of calcium homeostasis in familial dilated
cardiomyopathy: an in vitro analysis from an RBM20 patient-derived iPSC
model. Clin. Transl. Sci. 9, 158–167. doi: 10.1111/cts.12393
Wyles, S. P., Li, X., Hrstka, S. C., Reyes, S., Oommen, S., Beraldi, R., et al. (2016b).
Modeling structural and functional deficiencies of RBM20 familial dilated
cardiomyopathy using human induced pluripotent stem cells.Hum.Mol. Genet.
25, 254–265. doi: 10.1093/hmg/ddv468
Yasuda, S., Townsend, D., Michele, D. E., Favre, E. G., Day, S. M., and Metzger,
J. M. (2005). Dystrophic heart failure blocked by membrane sealant poloxamer.
Nature 436, 1025–1029.
Yermakovich, D., Sivitskaya, L., Vaikhanskaya, T., Danilenko, N., and Motuk, I.
(2018). Novel desmoplakin mutations in familial carvajal syndrome. Acta Myol.
7, 263–266.
Young, C. S., Hicks, M. R., Ermolova, N. V., Nakano, H., Jan, M., Younesi, S.,
et al. (2016). A single CRISPR-Cas9 deletion strategy that targets the majority of
DMD patients restores dystrophin function in hiPSC-derived muscle cells. Cell
Stem Cell 18, 533–540. doi: 10.1016/j.stem.2016.01.021
Zatti, S., Martewicz, S., Serena, E., Uno, N., Giobbe, G., Kazuki, Y., et al. (2014).
Complete restoration of multiple dystrophin isoforms in genetically corrected
Duchenne muscular dystrophy patient-derived cardiomyocytes. Mol. Ther.
Methods Clin. Dev. 1:1. doi: 10.1038/mtm.2013.1
Zaunbrecher, R. J., Abel, A. N., Beussman, K., Leonard, A., von Frieling-
Salewsky, M., Fields, P. A., et al. (2019). Cronos titin is expressed in human
cardiomyocytes and necessary for normal sarcomere function. Circulation 140,
1647–1660.
Zhan, H., Stanciauskas, R., Stigloher, C., Dizon, K. K., Jospin, M., Bessereau,
J. L., et al. (2014). In vivo single-molecule imaging identifies altered dynamics
of calcium channels in dystrophin-mutant C. elegans. Nat. Commun. 5:4974.
doi: 10.1038/ncomms5974
Zhang, Y., Long, C., Li, H., McAnally, J. R., Baskin, K. K., and Shelton,
J. M. (2017). CRISPR-Cpf1 correction of muscular dystrophy mutations in
human cardiomyocytes and mice. Sci. Adva. 3:e1602814. doi: 10.1126/sciadv.
1602814
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Pioner, Fornaro, Coppini, Ceschia, Sacconi, Donati, Favilli,
Poggesi, Olivotto and Ferrantini. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) and
the copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Physiology | www.frontiersin.org 22 May 2020 | Volume 11 | Article 368
